EP0225807B1 - Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein - Google Patents
Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein Download PDFInfo
- Publication number
- EP0225807B1 EP0225807B1 EP86309622A EP86309622A EP0225807B1 EP 0225807 B1 EP0225807 B1 EP 0225807B1 EP 86309622 A EP86309622 A EP 86309622A EP 86309622 A EP86309622 A EP 86309622A EP 0225807 B1 EP0225807 B1 EP 0225807B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- sequence
- complementary
- capturing
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *CC(C(C1)O[Si]I*)OC1N(C=CC(N1)=O)I1(O)=C Chemical compound *CC(C(C1)O[Si]I*)OC1N(C=CC(N1)=O)I1(O)=C 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/682—Signal amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Definitions
- This invention relates generally to a solution phase nucleic acid sandwich assay.
- EPA 123,300 describes biotin-avidin complexes for use in detecting nucleic acid sequences. Sung, in Nucl. Acids Res. 9 (22):6139-6151 (1981) and in J. Org. Chem. 47 :3623-3628 (1982), discusses the synthesis of a modified nucleotide and application of the modified structure in oligonucleotide synthesis. Modified nucleotides are also discussed in Draper, Nucleic Acids Res. 12 :2:989-1002 (1984), wherein it is suggested that cytidine residues in RNA be modified so as to bind to reporter molecules. Later work suggests similar modification of cytidine residues in DNA ( Anal. Chem. 157 (2):199 (1986). European Patent Application 063879, filed 6 April 1982, and PCT Application No. PCT/US84/00279 also describe modified nucleotides and applications thereof.
- analyses of DNA sequences have involved the binding of a sequence to a solid support and hybridization of a complementary sequence to the bound sequence.
- the annealing and complexing step usually involves an extended period of time and requires careful washing to minimize non-specific background signals.
- There is substantial interest in developing new techniques for analyzing nucleic acid sequences which are more rapid, minimize the number of manipulative steps, and provide for an increased signal to noise ratio.
- Copending European Patent Application No 90121584.8 which is divided from the present application is directed to polynucleotide probes useful in such techniques.
- the majority of polynucleotide probes in current use are radioactively labeled, e.g. with isotopes of hydrogen (3H), phosphorus (32P), carbon (14C) or iodine (125I).
- These materials are relatively simple to synthesize by direct inclusion of the radioactive moieties, e.g. by kinasing with 32P-labeled ATP, equilibrating with tritiated water, or the like.
- use of such radioactive labels has drawbacks, and other detectable species which are not radioactive are preferred.
- nucleotide modification is a difficult and sensitive procedure, as any modification reaction has to be mild enough to leave the RNA or DNA molecules intact, while giving a modified nucleotide product which can participate in normal base pairing and stacking interactions.
- nucleotide substitution positions typically limit nucleotide substitution positions to the 5-position of a pyrimidine and the 8-position of a purine, as noted in the literature ( see , e.g. , European Patent Application 063879, cited supra ).
- Base pairing may be hindered during hybridization if the detectable label is at one end of the nucleotide chain rather than present at some point within it. Further, it has proved difficult to provide even non-radioactively labeled probes which may be inexpensively synthesized in large quantity. Thus, many known probes are limited in their potential applications.
- the present invention for detecting particular nucleic acid sequences.
- Two sets of reagents are employed, which are referred to as the capturing set and the labeling set. Each set has at least two members.
- the labeling set has (1) a first probe set, which comprises one or a group of first analyte complementary sequence-first label reagent recognition sequence conjugate(s); and (2) one or a group of sequences complementary to said first recognition sequence-label conjugate(s).
- the capturing set has (1) a second probe set, which comprises one or a group of second analyte complementary sequence(s) joined to second capturing reagent polynucleotide recognition sequence(s); (2) one or a group of sequences complementary to said second capturing recognition sequence(s) bound to a separation member or preferably a first specific binding pair member to define the capturing conjugate; and (3) a separation member joined to a first complementary specific binding pair member when (2) does not have the separation member.
- the single stranded nucleic acid sample may be joined with the probes containing the complementary sequences of the two sets under annealing conditions, followed by the addition of the capturing and optionally the labeling conjugates to provide for the analyte complex with the specific binding pair member and optionally the label.
- the probe hybridized analyte sequence is separated by combining the complex with the separating means and separating probe bound analyte from unbound analyte.
- the first recognition sequence-label conjugate is added to the phase containing the separation member under hybridizing conditions. The label may then be detected in either phase.
- R1 is a reactive group derivatizable with a detectable label, which reactive group may be amine, carboxyl or thiol and further may be protected for various synthetic manipulations
- R2 is an optional linking moiety such as those typically used to label proteins, and includes an amide, thioether or disulfide linkage or a combination thereof
- R3 is selected from the group consisting of hydrogen, methyl, bromine, fluorine and iodine
- R4 is hydrogen, an anchoring group which covalently binds the structure to a solid support, or a blocking group such as dimethoxytrityl or pixyl, which blocking group is generally base-stable and acid-sensitive
- R5 is hydrogen, an anchoring group which covalently binds the structure to a solid support, or
- the copending application also describes nucleic acid probes using one or more of the above modified nucleotides.
- the probe can be used to screen a sample containing a plurality of single-stranded or double-stranded polynucleotide chains and will label the desired sequence, if present, by hybridization.
- Methods and compositions are provided for detecting a nucleic acid sequence by employing two sets of reagents.
- a detectable label may be separated into two phases in proportion to the amount of analyte present in a sample.
- Reagents containing complementary sequences can be added in excess during or at the end of the denaturation to inhibit renaturation of double stranded DNA and to react rapidly with the analyte strand by diffusion in solution.
- the rate of binding to the solid support can also be accelerated by the presence of a large amount of the binding pair member bound to the support.
- the analyte will be present in a highly concentrated form.
- the method involves two sets of reagents.
- the first set results in labeling the analyte sequence.
- the second set provides the means for separating label bound to analyte from unbound label in the assay medium.
- the first set will involve at least two reagents and may involve 10 to 30 reagents or more.
- the first reagent will be a subset of nucleic acid reagents and each member of the subset will have two nucleic acid regions.
- the first nucleic acid region of each member of the subset will be a region complementary to a sequence of the analyte.
- the second nucleotide sequence will be a recognition site for the labeling reagent. This second sequence will be selected, so as not to be encountered by endogenous sequences in the sample.
- the subsets will have regions complementary to the analyte sequence of at least 15 nucleotides (nt), usually at least 25nt, more usually at least 50nt, and not more than about 5kb, usually not more than about 1kb, preferably not more than about 100nt.
- the sequence complementary to the analyte may be joined to a non-specific sequence at either or both the 5 ⁇ and 3 ⁇ -termini.
- the non-complementary sequence if judiciously selected so as not to bind to sequences in the assay which could result in false positives, can be of any length, usually fewer than 10kb, more usually fewer than 5kb.
- the complementary sequences will be chosen so as to leave areas for binding of the other reagents to the analyte. Usually, areas of at least 25nt will be left available, where the analyte sequences complementary to the sequences of the individual members of the reagent subset may be substantially contiguous or separated and members of one subset may alternate with members of the other subset. The particular pattern of binding between the two subsets may vary widely depending on the sequences of the analyte.
- the reagent sequences may be prepared by synthesis in accordance with conventional procedures or by cloning and may be modified as appropriate for labeling.
- the set of sequences which are complementary to the analyte may be selected based on a variety of considerations. Depending upon the nature of the analyte, one may be interested in a consensus sequence, a sequence associated with polymorphisms, a particular phenotype or genotype, a particular strain, or the like. Thus, the labelling complementary sequences will be chosen in conjunction with the other complementary sequences of the capturing set to provide information concerning the analyte.
- the labeled sequence will include a sequence complementary to the first recognition sequence of the labeling probe(s).
- the labeling sequence will include one or more molecules, which directly or indirectly provide for a detectable signal.
- the labels may be bound to individual members of the complementary sequence or may be present as a terminal member or terminal tail having a plurality of labels.
- Various means for providing labels bound to the sequence have been reported in the literature. See, for example, Leary et al. , Proc. Natl. Acad. Sci. USA (1983) 80 :4045; Renz and Kurz, Nucl. Acids Res. (1984) 12 :3435; Richardson and Gumport, Nucl. Acids Res. (1983) 11 :6167; Smith et al ., Nucl. Acids Res. (1985) 13 :2399; Meinkoth and Wahl, Anal. Biochem. (1984) 138 :267.
- the labels may be bound either covalently or non-covalently to the complementary sequence.
- Labels which may be employed include radionuclides, fluorescers, chemiluminescers, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and the like.
- Illustrative specific labels include fluorescein, rhodamine. Texas red, phycoerythrin, umbelliferone, luminol, NADPH, ⁇ - ⁇ -galactosidase, horseradish peroxidase, etc.
- the labeled sequence can be conveniently prepared by synthesis.
- various labels may be joined through the functionality.
- the second set of reagents provides the means for separation of label bound to analyte from unbound label.
- the means for the separation or capturing means involves at least one capturing probe, usually a plurality of probes defining a subset, which includes two polynucleotide sequence regions that include a second subset of sequence complementary to the analyte, differing from the first subset of complementary sequences of the labeling probe and a recognition sequence, different from the first subset recognition sequence of the labeling probe.
- the second set of recognition sites for the capture probes may lie between the first set of recognition sites for the labeling probes as described above.
- the capturing sequences will be selected and synthesized in the same manner as described above using the considerations directing the selection for the labeling probes. Thus, the same constraints will be involved in preparing the capturing probes.
- separating means may be directly bound to a sequence complementary to the capturing recognition sequence, preferably a specific binding pair member will be bound to the complementary sequence.
- the specific binding pair member will be a ligand or receptor, preferably a ligand.
- Ligands may be any molecules for which a naturally occurring receptor exists or can be prepared. Thus, naturally occurring ligands may be exemplified by biotin, thyroxine, enyzme substrates, steroids, and the like. Instead of naturally occurring ligands, any hapten may be employed for the production of antibodies.
- Ligands will generally be at least about 125 molecular weight and usually less than about 5,000 molecular weight, more usually less than about 2,000 molecular weight, and preferably less than about 1,000 molecular weight.
- the receptors will generally be protein molecules and may include antibodies, naturally occurring proteins, such as avidin, thyroxine binding globulin, etc., lectins, enzymes, and the like.
- the receptors will generally be at least about 10,000 molecular weight, more usually 12,000 or more molecular weight, usually less than about one million molecular weight.
- the specific binding pair member may be joined to the second recognition sequence by any convenient means. As already indicated, the sequence may be synthesized, providing for a convenient functionality at the terminal base, which may then be used as the linkage site. One or a plurality of specific binding pair members may be joined to the complementary sequence, depending upon the particular choice of the specific binding pair member, its size, and the nature of the functionalities. Alternatively, for a large specific binding pair member, a plurality of sequences may be joined to the binding pair member. The capturing conjugate will be prepared, so that there will be little interference, if any, from the specific binding pair member with the annealing of the complementary recognition sequences and from duplex formation with the ligand-receptor binding.
- the receptor may be an additional nucleotide sequence that specifically recognizes the recognition sequence of the capturing probe.
- the separation means can be any support which allows for a rapid and clean separation of label bound to analyte from unbound label.
- the separation means may be particles, a solid wall surface of any of a variety of containers, e.g., centrifugal tubes, columns, microtiter plate wells, filters, tubing, etc.
- particles will be employed of a size in the range of about 0.4 to 200 ⁇ , more usually from about 0.8 to 4.0 ⁇ .
- the particles may be any convenient material, such as latex, glass, etc.
- homologous nucleic acid sequences need not have perfect complementarity to provide homoduplexes. In many situations, heteroduplexes will suffice where fewer than 15%, usually fewer than 10% of the bases are mismatches, ignoring loops of five or more members.
- Samples of analyte nucleic acids may be from a variety of sources, e.g., biological fluids or solids, food stuffs, environment materials, etc., and may be prepared for the hybridization analysis by a variety of means, e.g., proteinase K/SDS, chaotropic salts, etc. Also, it may be of advantage to decrease the average size of the analyte nucleic acids by enzymatic, physical or chemical means, e.g., restriction enzymes, sonication, chemical degradation (e.g., metal ions), etc.
- the fragments may be as small as O.1kb, usually being at least about O.5kb and may be 1kb or higher.
- the analyte sequence will be provided in single stranded form. Where the sequence is naturally present in single stranded form, denaturation will not be required. However, where the sequence is present in double stranded form, the sequence will be denatured. Denaturation can be carried out by various techniques, such as alkali, generally from about 0.05 to O.2M hydroxide, formamide, detergents, heat, or combinations thereof. Denaturation can be carried out in the presence of the labeling probe and/or the capturing probe, so that upon change of conditions to annealing conditions, the probes will bind to any complementary sequences which are present. For example, where heat and alkali are employed, by neutralization and cooling, annealing will occur.
- denaturation may occur in the presence of the probes, whereupon cooling rapid annealing of the probes to the single-stranded DNA may occur, followed by the addition of the other reagents at lower temperatures and, as appropriate, under milder conditions, such as neutral pH, reduced ionic strength, or the like.
- the ratio of probe to anticipated moles of analyte will be at least 1:1, preferably at least about 1.5:1, and more preferably 2:1 and may be as high as 100:1 or higher. Concentrations of each of the probes will generally range from about 10 ⁇ 9 to 10 ⁇ 6M, with sample nucleic acid concentrations varying from 10 ⁇ 21 to 10 ⁇ 12M.
- the labeled first recognition sequence and the capturing second recognition sequence are added and allowed to hybridize.
- the labeled first recognition sequence can be added after capture and separation.
- a preferred embodiment which greatly reduces background and provides for extraordinarily high sensitivity will employ the following sequence.
- the analyte With double-stranded analyte, the analyte will be denatured in the presence of the probe or complementary sequences, or the probes may be added shortly after denaturation, and under annealing conditions. After sufficient time for annealing, the complexes may then be combined with the separation means, whereby the complexes will be bound to the support. Any background DNA or non-specifically bound DNA may be washed away so as to avoid non-specific binding of label in the next step. The solid support may then be washed to remove any non-specifically bound label to provide for a substantially reduced background of non-specifically bound label.
- the analyte which is the long bar at the top is combined with the A and B probes, where A provides the complementary sequence for the label conjugate and B provides the complementary sequence for the specific binding pair member, in this case, biotin.
- a and B probes and the analyte would be joined together under annealing conditions, whereby complex formation would occur between the probes and the analyte.
- the biotin conjugate, B ⁇ could be included with the probes or be added in a separate step to the solution containing the analyte complexes. After sufficient time for B ⁇ to anneal to B, the resulting biotinylated analyte complex would then be added to the solid support to which avidin is bound.
- the solid support could be washed free of any non-specific DNA, followed by the addition of the labeled sequence, which in this case is indicated as being fluorescein bound to A ⁇ .
- the labeled sequence would be added under annealing conditions and after sufficient time for duplex formation, non-specifically bound and excess labeled conjugate would be washed away and the fluorescence of the surface determined.
- a somewhat shorter protocol is provided by the configuration depicted in part 1 of Figure 1.
- the probes A and B would be added to the analyte under annealing conditions, whereby analyte complexes would form.
- the analyte complex solution would then be added to the solid support for sufficient time for the capturing probes to bind to the solid support by complex formation with the sequence indicated as B ⁇ C.
- Excess DNA could be washed away, followed by the addition of the fluorescein labeled sequence A ⁇ , and the mixture allowed to anneal for sufficient time for complex formation to occur between the label and the probes.
- Excess in non-specifically bound label could then be washed away to provide the configuration depicted in Figure 1, part 1.
- the denaturing step will take from about 5 to 25 minutes, usually from about 5 to 15 minutes, while the annealing step will generally take from about 30 minutes to 2 hours, frequency being completed in about 1 hour.
- Annealing can be carried out at a mildly elevated temperature, generally in the range from about 20°C to 50°C, more usually from about 25°C to 40°C, particularly 37°C.
- an aqueous medium is employed, particularly a buffered aqueous medium, which may include various additives.
- Additives which may be employed include low concentrations of detergent (0.1 to 1%, salts, e.g., sodium citrate (0.017 to 0.170M), Ficoll, polyvinylpyrrolidone, carrier nucleic acids, carrier proteins, etc.
- various solvents may be added to the aqueous medium, such as dimethylformamide, dimethylsulfoxide, and formamide. These other solvents will be present in amounts ranging from 2 to 50%.
- the stringency of the annealing medium may be controlled by temperature, salt concentration, solvent system, and the like. Thus, depending upon the length and nature of the sequence of interest, the stringency will be varied.
- the medium may be changed to optimize or approximately optimize the conditions for specific binding pair complex formation.
- the pH will usually be modified to be in the range of about 6 to 9, preferably about 7.
- This medium may be added in conjunction with the separation means and the mixture allowed to incubate for at least 5min., usually about 10min., and less than about 60min., usually about 15 to 45min., more usually about 30min. being satisfactory.
- the phases may then be separated in accordance with the nature of the separation means.
- centrifugation or filtration will provide for separation of the particles, discarding the supernatant or isolating the supernatant.
- the particles will be washed thoroughly, usually from one to five times, with an appropriate buffered medium, e.g., PBS.
- PBS buffered medium
- Nucleic acid probes useful in conjunction with the above assay method are probes which are prepared from one or more modified nucleotides. As noted above, these nucleotides and probes are fully described in copending European Patent Application No 90121584.8.
- Label conjugate (A ⁇ ) for DNA or avidin support Fluorescein - 5 ⁇ CTGAACGTTCAACCAGTTCA 3 ⁇ DNA sequence (B ⁇ C) bound to solid support: 3 ⁇ GAAGAAACCTCTTTCACCACTGTCATCAAAAGGTTAACCATGTTTCTTGT 5 ⁇ Biotin conjugate (B') for avidin support: Biotin - 5' CACCACTTTCTCCAAAGAAG 3'
- N4 - (2' - aminoethyl) - deoxycytosine - DNA The analyte is an HBV BglII fragment as indicated above. (Valenzuela et al . (1981) in Animal Virus Genetics, eds. Fields, B., Jaenisch, R., Fox, C.F., Academic Press, Inc., N.Y., pp 57-70.) A subset of labeling and capturing probes are indicated, where 12 different sequences complementary to different sequences present in HBV are provided. Six of the HBV complementary sequences are joined to a common sequence (A) for complexing with the label conjugate (A').
- HBV complementary sequences are joined to a common sequence (B) for complexing with a biotinylated sequence (B') or a third DNA sequence (B'C) for binding to a support.
- B common sequence
- B' biotinylated sequence
- B'C third DNA sequence
- the corresponding 5 ⁇ -DMT-3 ⁇ -phosphoramidite N4-(2-N-trifluoroacetylaminoethyl) deoxycytidine was prepared by blocking the alkylamine with trifluoroacetic anhydride and then preparing the corresponding N,N-diisopropyl phosphoramidite as described (Beaucage and Caruthers, supra ; McBride and Caruthers, Tetrahedron Lett. 24:245 (1983)).
- Synthetic oligonucleotides were prepared by an automated phosphoramidite method as described in Warner et al., DNA 3 :401 (1984). Purification was carried out according to Sanchez-Pescador and Urdea, DNA 3 :339 (1984).
- the aminoethyl derivative of deoxycytidine as prepared in Example 2 was incorporated by standard coupling procedures during the oligonucleotide synthesis and the purified modified oligonucleotides were used for incorporation of a fluorescein label as follows.
- To a dried sample (3-5 OD 260 units) of the aminoethyl deoxycytidine containing oligomer were added 50 ⁇ l of DMF and 25 ⁇ l of the 0.M2 stock solution of A described above. After 18 h at room temperature, the solution was partially purified by Sephadex G-10 chromatography eluted with water, dried and further purified by polyacrylamide gel, as above.
- biotin labeling was achieved as follows.
- the oligonucleotide (3-5 OD 260 units) was taken up in 50 ⁇ l 0.M1 sodium phosphate, pH 7.0 and 50 ⁇ l of DMF to which 100 ⁇ l of a DMF solution containing 1 mg of a "long chain" N-hydroxysuccinimidyl biotin (Pierce Chemical) was added. After 18 h at room temperature, the biotinylated probe was purified as described for the fluorescein labeled probe.
- Fragment B ⁇ C (a synthetic 50mer) was 5 ⁇ -phosphorylated with T4-polynucleotide kinase and ATP using standard conditions. After gel purification as described above, the oligonucleotide was dried by evacuation.
- Hydroxylated latex (1Omg; 0.8 ⁇ ; Pandex Laboratories) was washed with DMSO, then three portions of 40mM MES (morpholinoethanesulfonic acid), pH 6.0 by centrifugation. 1500pmoles of 5 ⁇ -phosphorylated fragment B ⁇ C was taken up in 90ml of 40mM MES and added to the washed support. A solution was prepared to contain 100mg of EDAC in 100ml of MES. After adding 5 ⁇ l of the EDAC solution and mixing, the reaction mixture was evaporated until 30 ⁇ l total remained. The mixture was left at 37°C for 18h, then centrifuged for 2min at 12,000rpm. The supernatant was discarded.
- MES morpholinoethanesulfonic acid
- the latex was suspended in 30ml of DMSO, vortexed, 100 ⁇ l of water was added, the mixture vortexed for 2min and the supernatant was discarded after centrifugation. This washing process was repeated twice. The support was then washed three times with 100ml portions of 4xSSC, H2O, then H2O at 37°C for 15min (yield 20 picomoles fragment B ⁇ C per mg of latex).
- a pBR322 clone containing the entire HBV genome (Valenzuela et al ., Animal Virus Genetics , R. Jaenisch, B. Fields and C.F. Fox, Eds. (Academic Press: New York) pp. 57-70 (1980)) was cut with BglII and used as the analyte nucleic acid.
- Analyte in 10ml of formamide containing 6 picomoles of the labeling and capturing probe sets was heated to 95°C for 10min and cooled to room temperature. To this mixture, 60 ⁇ l of water, 20 ⁇ l of 20xSSC, 10ml of 1% NP40 and 2 ⁇ l (10 ⁇ g) of polyA are added, vortexed and incubated at 37°C for 1h.
- the solid supported DNA probes (8 picomoles 400vg) is added and incubated for an additional 1.5h. The mixture is centrifuged at 12,000rpm for 2min and the supernatant discarded. The support is washed once by vortexing the pellet into solution with 100ml of 4xSSC, followed by centrifugation. To the washed beads are added a mixture of 4ml of 20xSSC, 2 ⁇ l of 1% NP40, 1 ⁇ l (5 ⁇ g) polyA, 13 ⁇ l of water and 6 picomoles of fluorescein labeled probe.
- the beads are transferred to a Pandex filter plate, washed four times with 100ml of 4xSSC by vacuum filtration on the O.2 ⁇ cellulose acetate membrane of the plate.
- the sample is vacuumed to dryness and read on the fluorescein channel A( ⁇ excitation -485; ⁇ emission -525) of the Pandex screen machine.
- the HBV plasmid was sonicated to an average size of 500bp.
- the denaturation and hybridization were carried out as above except that 30 picomoles of labeling and capturing probes were used and a 5h annealing was employed.
- a fluorescein probe was added and incubation was carried out for 1h followed by washing and reading on the Screen Machine as described above.
- 10 OD 260 units dissolved in 50 ⁇ l of water were added 10 ⁇ l of 1.0 M sodium borate, pH 9.3, and 500 ⁇ l of distilled dimethylformamide containing 20 mg of p-phenylene diisothiocyanate. The solution was vortexed and set for 2 hr at room temperature in the dark. Approximately 3 ml of n-butanol was then
- UV-shadowed bands were taken with a Polaroid MP-4 camera system fitted with a Kodak No. 59 green filter, after which the bands were cut out with a razor blade.
- the bands were put into a 10-ml Bio-Rad polypropylene econo-columns to which 3 ml of 0.1 M sodium phosphate, pH 7.5, was added, then set at room temperature overnight.
- the contents of the column were filtered through the frit at the column bottom into an Amicon Centricon microconcentrator that had been washed twice with distilled water.
- the HRP-DNA conjugate was then concentrated by centrifugation at 3500 rpm and washed twice with 1x PBS also by centrifugation. The final solution was then stored at 4°C.
- Biotin labeled probe (B ⁇ ; 1000 pmoles in 66.7 ⁇ l of water) was combined with 5 ml of a 0.25 % (w/v) solution of 0.8 ⁇ avidin beads (Pandex laboratories), 1 ml of 20x SSC, 0.5 ml of 1% NP40 and 0.6 ml of 1 mg/ml polyA. After 1 h at 37°C, the beads were washed twice by centrifugation with 4x SSC, 0.1% NP40 then stored in 2.5 ml of this solution.
- the HBV analyte (described above) in 3 ⁇ l water was diluted into 10 ⁇ l of 4x SSC, 1% SDS, 0.5 M NaOH and 1.5 pmoles of the labeling and capturing probe sets.
- the mixture was heated to 95°C for 10 min., cooled on ice and neutralized with 5 ⁇ l of 1 M acetic acid, then 10 ⁇ l of the biotin probe beads were added and the solution was incubated at 37°C for 1 h.
- the beads were washed twice by centrifugation with 4x SSC, 0.1% NP40, then taken up in 50 ⁇ l of 0.1% NP40, 1 mg/ml polyA, 10 mg/ml BSA, 1X PBS containing 1 pmole of HRP-DNA conjugate and set a 37°C for 1 h.
- the beads were washed with 0.1% NP40, 1X PBS three times then transferred in 50 ⁇ l to a microtiter dish.
- 50 ⁇ l of fresh OPD solution 98 mg OPD (O-phenylenediamine), 20 ⁇ l of 30% H2O2 in 10 ml of 50 mM sodium citrate pH 5.0
- the absorbances were recorded on a microtiter plate reader. Control hybridizations contained no HBV analyte.
Abstract
Description
- This invention relates generally to a solution phase nucleic acid sandwich assay.
- Meinkoth and Wahl, Anal. Biochem., (1984) 138:267-284, provide a review article of hybridization techniques. See also Leary et al., Proc. Natl. Acad. Sci. USA (1983) 80:4045-4049, for a description of the dot blot assay. Sandwich hybridization is described by Ranki et al., Curr. Top. Microbiol. Immunology (1983) pp. 308ff. See also Ranki et al., Gene (1983) 21:77-85, Virtanen et al., Lancet (1983) 381-383, and U.S. Patent No. 4,486,539. EPA 123,300 describes biotin-avidin complexes for use in detecting nucleic acid sequences. Sung, in Nucl. Acids Res. 9(22):6139-6151 (1981) and in J. Org. Chem. 47:3623-3628 (1982), discusses the synthesis of a modified nucleotide and application of the modified structure in oligonucleotide synthesis. Modified nucleotides are also discussed in Draper, Nucleic Acids Res. 12:2:989-1002 (1984), wherein it is suggested that cytidine residues in RNA be modified so as to bind to reporter molecules. Later work suggests similar modification of cytidine residues in DNA (Anal. Chem. 157(2):199 (1986). European Patent Application 063879, filed 6 April 1982, and PCT Application No. PCT/US84/00279 also describe modified nucleotides and applications thereof.
- The increasing ease of cloning and synthesizing DNA sequences has greatly expanded opportunities for detecting particular nucleic acid sequences of interest. No longer must one rely on the use of immunocomplexes for the detection of pathogens, lesions, antigens, and the like. Rather than detecting particular determinant sites, one can detect DNA sequences or RNA sequences associated with a particular cell. In this manner, diseases can be diagnosed, phenotypes and genotypes can be analyzed, as well as polymorphisms, relationships between cells, and the like.
- For the most part, analyses of DNA sequences have involved the binding of a sequence to a solid support and hybridization of a complementary sequence to the bound sequence. The annealing and complexing step usually involves an extended period of time and requires careful washing to minimize non-specific background signals. There is substantial interest in developing new techniques for analyzing nucleic acid sequences, which are more rapid, minimize the number of manipulative steps, and provide for an increased signal to noise ratio.
- Copending European Patent Application No 90121584.8, which is divided from the present application is directed to polynucleotide probes useful in such techniques. The majority of polynucleotide probes in current use are radioactively labeled, e.g. with isotopes of hydrogen (³H), phosphorus (³²P), carbon (¹⁴C) or iodine (¹²⁵I). These materials are relatively simple to synthesize by direct inclusion of the radioactive moieties, e.g. by kinasing with ³²P-labeled ATP, equilibrating with tritiated water, or the like. As is well known, however, use of such radioactive labels has drawbacks, and other detectable species which are not radioactive are preferred.
- In order to incorporate other, non-radioactive types of detectable species in a nucleotide, some sort of chemical modification of the nucleotide is required. It is widely recognized that nucleotide modification is a difficult and sensitive procedure, as any modification reaction has to be mild enough to leave the RNA or DNA molecules intact, while giving a modified nucleotide product which can participate in normal base pairing and stacking interactions. These considerations typically limit nucleotide substitution positions to the 5-position of a pyrimidine and the 8-position of a purine, as noted in the literature (see, e.g., European Patent Application 063879, cited supra).
- Other considerations must also be taken into account. Base pairing may be hindered during hybridization if the detectable label is at one end of the nucleotide chain rather than present at some point within it. Further, it has proved difficult to provide even non-radioactively labeled probes which may be inexpensively synthesized in large quantity. Thus, many known probes are limited in their potential applications.
- Methods and compositions are provided by the present invention for detecting particular nucleic acid sequences. Two sets of reagents are employed, which are referred to as the capturing set and the labeling set. Each set has at least two members. The labeling set has (1) a first probe set, which comprises one or a group of first analyte complementary sequence-first label reagent recognition sequence conjugate(s); and (2) one or a group of sequences complementary to said first recognition sequence-label conjugate(s). The capturing set has (1) a second probe set, which comprises one or a group of second analyte complementary sequence(s) joined to second capturing reagent polynucleotide recognition sequence(s); (2) one or a group of sequences complementary to said second capturing recognition sequence(s) bound to a separation member or preferably a first specific binding pair member to define the capturing conjugate; and (3) a separation member joined to a first complementary specific binding pair member when (2) does not have the separation member.
- The single stranded nucleic acid sample may be joined with the probes containing the complementary sequences of the two sets under annealing conditions, followed by the addition of the capturing and optionally the labeling conjugates to provide for the analyte complex with the specific binding pair member and optionally the label. The probe hybridized analyte sequence is separated by combining the complex with the separating means and separating probe bound analyte from unbound analyte. Where the label has not been previously added, the first recognition sequence-label conjugate is added to the phase containing the separation member under hybridizing conditions. The label may then be detected in either phase.
- The aforementioned copending European Patent Application No 90121584.8 describes modified derivatizable nucleotides having the structure of Formula 1, and their preparation including the step of derivatising the R¹ moiety with a detectable label:
wherein R¹ is a reactive group derivatizable with a detectable label, which reactive group may be amine, carboxyl or thiol and further may be protected for various synthetic manipulations, R² is an optional linking moiety such as those typically used to label proteins, and includes an amide, thioether or disulfide linkage or a combination thereof, R³ is selected from the group consisting of hydrogen, methyl, bromine, fluorine and iodine, R⁴ is hydrogen, an anchoring group which covalently binds the structure to a solid support, or a blocking group such as dimethoxytrityl or pixyl, which blocking group is generally base-stable and acid-sensitive, R⁵ is hydrogen, an anchoring group which covalently binds the structure to a solid support, or a phosphorus derivative enabling addition of nucleotides at the 3' position, and may be, for example, PO₃H₂, a phosphotriester, a phosphodiester, a phosphite, a phosphoramidite, H-phosphonate or a phosphorothioate, and R⁶ is H, OH, or OR where R is a functional group useful as a protecting moiety in RNA synthesis, and x is an integer in the range of 1 and 8 inclusive. - The copending application also describes nucleic acid probes using one or more of the above modified nucleotides. The probe can be used to screen a sample containing a plurality of single-stranded or double-stranded polynucleotide chains and will label the desired sequence, if present, by hybridization.
- In the accompanying drawing:-
- Figure 1 is an illustrative depiction of a complex from the various components bound to a solid support (1) using DNA bridges for non-covalent binding and (2) using biotin-avidin bridges for non-covalent binding.
- Methods and compositions are provided for detecting a nucleic acid sequence by employing two sets of reagents. By using combinations of nucleic acid sequences complementary to a nucleic acid analyte and to arbitrary sequences and specific binding pair members, a detectable label may be separated into two phases in proportion to the amount of analyte present in a sample. By providing for annealing of nucleic acid sequences in solution, the time for performing the assay can be substantially diminished as compared to annealing on a solid surface and the number of separations and washing steps required can be limited and be less critical, so as to reduce technician error. Reagents containing complementary sequences can be added in excess during or at the end of the denaturation to inhibit renaturation of double stranded DNA and to react rapidly with the analyte strand by diffusion in solution. The rate of binding to the solid support can also be accelerated by the presence of a large amount of the binding pair member bound to the support. In addition, by adding the label conjugate as the last reagent, the analyte will be present in a highly concentrated form.
- As indicated above, the method involves two sets of reagents. The first set results in labeling the analyte sequence. The second set provides the means for separating label bound to analyte from unbound label in the assay medium.
- The first set, the labeling set, will involve at least two reagents and may involve 10 to 30 reagents or more. The first reagent will be a subset of nucleic acid reagents and each member of the subset will have two nucleic acid regions. The first nucleic acid region of each member of the subset will be a region complementary to a sequence of the analyte. The second nucleotide sequence will be a recognition site for the labeling reagent. This second sequence will be selected, so as not to be encountered by endogenous sequences in the sample.
- The subsets will have regions complementary to the analyte sequence of at least 15 nucleotides (nt), usually at least 25nt, more usually at least 50nt, and not more than about 5kb, usually not more than about 1kb, preferably not more than about 100nt. The sequence complementary to the analyte may be joined to a non-specific sequence at either or both the 5ʹ and 3ʹ-termini. The non-complementary sequence, if judiciously selected so as not to bind to sequences in the assay which could result in false positives, can be of any length, usually fewer than 10kb, more usually fewer than 5kb.
- The complementary sequences will be chosen so as to leave areas for binding of the other reagents to the analyte. Usually, areas of at least 25nt will be left available, where the analyte sequences complementary to the sequences of the individual members of the reagent subset may be substantially contiguous or separated and members of one subset may alternate with members of the other subset. The particular pattern of binding between the two subsets may vary widely depending on the sequences of the analyte.
- The reagent sequences may be prepared by synthesis in accordance with conventional procedures or by cloning and may be modified as appropriate for labeling.
- The set of sequences which are complementary to the analyte may be selected based on a variety of considerations. Depending upon the nature of the analyte, one may be interested in a consensus sequence, a sequence associated with polymorphisms, a particular phenotype or genotype, a particular strain, or the like. Thus, the labelling complementary sequences will be chosen in conjunction with the other complementary sequences of the capturing set to provide information concerning the analyte.
- The labeled sequence will include a sequence complementary to the first recognition sequence of the labeling probe(s). The labeling sequence will include one or more molecules, which directly or indirectly provide for a detectable signal. The labels may be bound to individual members of the complementary sequence or may be present as a terminal member or terminal tail having a plurality of labels. Various means for providing labels bound to the sequence have been reported in the literature. See, for example, Leary et al., Proc. Natl. Acad. Sci. USA (1983) 80:4045; Renz and Kurz, Nucl. Acids Res. (1984) 12:3435; Richardson and Gumport, Nucl. Acids Res. (1983) 11:6167; Smith et al., Nucl. Acids Res. (1985) 13:2399; Meinkoth and Wahl, Anal. Biochem. (1984) 138:267. The labels may be bound either covalently or non-covalently to the complementary sequence.
- Labels which may be employed include radionuclides, fluorescers, chemiluminescers, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and the like. Illustrative specific labels include fluorescein, rhodamine. Texas red, phycoerythrin, umbelliferone, luminol, NADPH, α-β-galactosidase, horseradish peroxidase, etc.
- The labeled sequence can be conveniently prepared by synthesis. By providing for a terminal group which has a convenient functionality, various labels may be joined through the functionality. Thus, one can provide for a carboxy, thiol, amine, hydrazine or other functionality to which the various labels may be joined without detrimentally affecting duplex formation with the sequence. As already indicated, one can have a molecule with a plurality of labels joined to the sequence complementary to the labeling sequence. Alternatively, one may have a ligand bound to the labeling sequence and use a labeled receptor for binding to the ligand to provide the labeled analyte complex.
- The second set of reagents provides the means for separation of label bound to analyte from unbound label. The means for the separation or capturing means involves at least one capturing probe, usually a plurality of probes defining a subset, which includes two polynucleotide sequence regions that include a second subset of sequence complementary to the analyte, differing from the first subset of complementary sequences of the labeling probe and a recognition sequence, different from the first subset recognition sequence of the labeling probe. The second set of recognition sites for the capture probes may lie between the first set of recognition sites for the labeling probes as described above. The capturing sequences will be selected and synthesized in the same manner as described above using the considerations directing the selection for the labeling probes. Thus, the same constraints will be involved in preparing the capturing probes.
- While the separating means may be directly bound to a sequence complementary to the capturing recognition sequence, preferably a specific binding pair member will be bound to the complementary sequence. The specific binding pair member will be a ligand or receptor, preferably a ligand. Ligands may be any molecules for which a naturally occurring receptor exists or can be prepared. Thus, naturally occurring ligands may be exemplified by biotin, thyroxine, enyzme substrates, steroids, and the like. Instead of naturally occurring ligands, any hapten may be employed for the production of antibodies. Ligands will generally be at least about 125 molecular weight and usually less than about 5,000 molecular weight, more usually less than about 2,000 molecular weight, and preferably less than about 1,000 molecular weight.
- The receptors will generally be protein molecules and may include antibodies, naturally occurring proteins, such as avidin, thyroxine binding globulin, etc., lectins, enzymes, and the like. The receptors will generally be at least about 10,000 molecular weight, more usually 12,000 or more molecular weight, usually less than about one million molecular weight.
- The specific binding pair member may be joined to the second recognition sequence by any convenient means. As already indicated, the sequence may be synthesized, providing for a convenient functionality at the terminal base, which may then be used as the linkage site. One or a plurality of specific binding pair members may be joined to the complementary sequence, depending upon the particular choice of the specific binding pair member, its size, and the nature of the functionalities. Alternatively, for a large specific binding pair member, a plurality of sequences may be joined to the binding pair member. The capturing conjugate will be prepared, so that there will be little interference, if any, from the specific binding pair member with the annealing of the complementary recognition sequences and from duplex formation with the ligand-receptor binding.
- Alternatively, the receptor may be an additional nucleotide sequence that specifically recognizes the recognition sequence of the capturing probe.
- The separation means can be any support which allows for a rapid and clean separation of label bound to analyte from unbound label. Thus, the separation means may be particles, a solid wall surface of any of a variety of containers, e.g., centrifugal tubes, columns, microtiter plate wells, filters, tubing, etc. Preferably, particles will be employed of a size in the range of about 0.4 to 200µ, more usually from about 0.8 to 4.0µ. The particles may be any convenient material, such as latex, glass, etc.
- The homologous nucleic acid sequences need not have perfect complementarity to provide homoduplexes. In many situations, heteroduplexes will suffice where fewer than 15%, usually fewer than 10% of the bases are mismatches, ignoring loops of five or more members.
- Samples of analyte nucleic acids may be from a variety of sources, e.g., biological fluids or solids, food stuffs, environment materials, etc., and may be prepared for the hybridization analysis by a variety of means, e.g., proteinase K/SDS, chaotropic salts, etc. Also, it may be of advantage to decrease the average size of the analyte nucleic acids by enzymatic, physical or chemical means, e.g., restriction enzymes, sonication, chemical degradation (e.g., metal ions), etc. The fragments may be as small as O.1kb, usually being at least about O.5kb and may be 1kb or higher.
- In carrying out the method, the analyte sequence will be provided in single stranded form. Where the sequence is naturally present in single stranded form, denaturation will not be required. However, where the sequence is present in double stranded form, the sequence will be denatured. Denaturation can be carried out by various techniques, such as alkali, generally from about 0.05 to O.2M hydroxide, formamide, detergents, heat, or combinations thereof. Denaturation can be carried out in the presence of the labeling probe and/or the capturing probe, so that upon change of conditions to annealing conditions, the probes will bind to any complementary sequences which are present. For example, where heat and alkali are employed, by neutralization and cooling, annealing will occur.
- In many situations, it will be preferable to avoid having either the label or the separation means present during denaturation. The elevated temperatures, the non-aqueous solvents, the salts, or other materials present during denaturation may result in degradation, or undesirable modification of the label and/or separation means. Therefore, in many situations, denaturation may occur in the presence of the probes, whereupon cooling rapid annealing of the probes to the single-stranded DNA may occur, followed by the addition of the other reagents at lower temperatures and, as appropriate, under milder conditions, such as neutral pH, reduced ionic strength, or the like.
- Normally, the ratio of probe to anticipated moles of analyte will be at least 1:1, preferably at least about 1.5:1, and more preferably 2:1 and may be as high as 100:1 or higher. Concentrations of each of the probes will generally range from about 10⁻⁹ to 10⁻⁶M, with sample nucleic acid concentrations varying from 10⁻²¹ to 10⁻¹²M.
- After annealing conditions have been achieved, or even prior to such time, the labeled first recognition sequence and the capturing second recognition sequence are added and allowed to hybridize. Alternatively, the labeled first recognition sequence can be added after capture and separation.
- A preferred embodiment which greatly reduces background and provides for extraordinarily high sensitivity will employ the following sequence. With double-stranded analyte, the analyte will be denatured in the presence of the probe or complementary sequences, or the probes may be added shortly after denaturation, and under annealing conditions. After sufficient time for annealing, the complexes may then be combined with the separation means, whereby the complexes will be bound to the support. Any background DNA or non-specifically bound DNA may be washed away so as to avoid non-specific binding of label in the next step. The solid support may then be washed to remove any non-specifically bound label to provide for a substantially reduced background of non-specifically bound label.
- Consider Figure 1,
part 2. In effect, the analyte which is the long bar at the top is combined with the A and B probes, where A provides the complementary sequence for the label conjugate and B provides the complementary sequence for the specific binding pair member, in this case, biotin. Thus, the A and B probes and the analyte would be joined together under annealing conditions, whereby complex formation would occur between the probes and the analyte. The biotin conjugate, Bʹ could be included with the probes or be added in a separate step to the solution containing the analyte complexes. After sufficient time for Bʹ to anneal to B, the resulting biotinylated analyte complex would then be added to the solid support to which avidin is bound. After sufficient time for the specific binding pair members to form complexes, the solid support could be washed free of any non-specific DNA, followed by the addition of the labeled sequence, which in this case is indicated as being fluorescein bound to Aʹ. The labeled sequence would be added under annealing conditions and after sufficient time for duplex formation, non-specifically bound and excess labeled conjugate would be washed away and the fluorescence of the surface determined. - A somewhat shorter protocol is provided by the configuration depicted in part 1 of Figure 1. In this situation, the probes A and B would be added to the analyte under annealing conditions, whereby analyte complexes would form. After sufficient time for analyte complexes to form, the analyte complex solution would then be added to the solid support for sufficient time for the capturing probes to bind to the solid support by complex formation with the sequence indicated as BʹC. Excess DNA could be washed away, followed by the addition of the fluorescein labeled sequence Aʹ, and the mixture allowed to anneal for sufficient time for complex formation to occur between the label and the probes. Excess in non-specifically bound label could then be washed away to provide the configuration depicted in Figure 1, part 1.
- Usually, the denaturing step will take from about 5 to 25 minutes, usually from about 5 to 15 minutes, while the annealing step will generally take from about 30 minutes to 2 hours, frequency being completed in about 1 hour. Annealing can be carried out at a mildly elevated temperature, generally in the range from about 20°C to 50°C, more usually from about 25°C to 40°C, particularly 37°C.
- Usually, an aqueous medium is employed, particularly a buffered aqueous medium, which may include various additives. Additives which may be employed include low concentrations of detergent (0.1 to 1%, salts, e.g., sodium citrate (0.017 to 0.170M), Ficoll, polyvinylpyrrolidone, carrier nucleic acids, carrier proteins, etc. Depending upon the nature of the specific binding pair members, various solvents may be added to the aqueous medium, such as dimethylformamide, dimethylsulfoxide, and formamide. These other solvents will be present in amounts ranging from 2 to 50%.
- The stringency of the annealing medium may be controlled by temperature, salt concentration, solvent system, and the like. Thus, depending upon the length and nature of the sequence of interest, the stringency will be varied.
- For the separation step, for example, using a ligand-receptor pair, the medium may be changed to optimize or approximately optimize the conditions for specific binding pair complex formation. Thus, the pH will usually be modified to be in the range of about 6 to 9, preferably about 7. This can be readily achieved, by adding from about 0.5 to 2, usually about 1 volume of about a 0.1 to 0.5M buffered medium, e.g., phosphate buffered saline, to the annealing medium. This medium may be added in conjunction with the separation means and the mixture allowed to incubate for at least 5min., usually about 10min., and less than about 60min., usually about 15 to 45min., more usually about 30min. being satisfactory.
- The phases may then be separated in accordance with the nature of the separation means. For particles, centrifugation or filtration will provide for separation of the particles, discarding the supernatant or isolating the supernatant. Where the particles are assayed, the particles will be washed thoroughly, usually from one to five times, with an appropriate buffered medium, e.g., PBS. When the separation means is a wall or support, the supernatant may be isolated or discarded and the wall washed in the same manner as indicated for the particles.
- Depending upon the nature of the label, various techniques can be employed for detecting the presence of the label. For fluorescers, a large number of different fluorometers are available. With enzymes, either a fluorescent or a colored product can be provided and determined fluorometrically, spectrophoto metrically or visually. The various labels which have been employed in immunoassays and the techniques applicable to immunoassays can be employed with the subject assays.
- Nucleic acid probes useful in conjunction with the above assay method are probes which are prepared from one or more modified nucleotides. As noted above, these nucleotides and probes are fully described in copending European Patent Application No 90121584.8.
- It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description as well as the Examples which follow are intended to illustrate and not limit the scope of the invention. The following experimental and exemplifying material includes, inter alia and for convenience and completeness, description of nucleotide and probe preparation although these aspects are not aspects of the present invention as such. Again, the reader is referred to copending European Patent Application No 90121584.8.
Label conjugate (Aʹ) for DNA or avidin support:
Fluorescein - 5ʹ CTGAACGTTCAACCAGTTCA 3ʹ
DNA sequence (BʹC) bound to solid support:
3ʹ GAAGAAACCTCTTTCACCACTGTCATCAAAAGGTTAACCATGTTTCTTGT 5ʹ
Biotin conjugate (B') for avidin support:
Biotin - 5' CACCACTTTCTCCAAAGAAG 3' -
N⁴ - (2' - aminoethyl) - deoxycytosine - DNA
The analyte is an HBV BglII fragment as indicated above. (Valenzuela et al. (1981) in Animal Virus Genetics, eds. Fields, B., Jaenisch, R., Fox, C.F., Academic Press, Inc., N.Y., pp 57-70.) A subset of labeling and capturing probes are indicated, where 12 different sequences complementary to different sequences present in HBV are provided. Six of the HBV complementary sequences are joined to a common sequence (A) for complexing with the label conjugate (A'). The other six HBV complementary sequences are joined to a common sequence (B) for complexing with a biotinylated sequence (B') or a third DNA sequence (B'C) for binding to a support. In Figure 1 is shown an illustration of the final complex involving the HBV strand and the various reagents. -
To 1 mmole of fluorescein isothiocyanate in 5 ml of DMF was added 2 mmole of 6-aminocaproic acid and 540 µl of triethylamine. After 24 h at room temperature, the product was isolated by preparative thin layer chromatography (Warner and Legg, Inorg. Chem. 18:1839 (1979)). The dried product was suspended in 10 ml of 1:1 DMF/THF (v/v) to which 1.5 mmole of N-hydroxy succinimide and 1 mmole of dicyclohexylcarbodiimide were added. After 18 h at room temperature the solution was filtered through glass wool and diluted to a 0.2M final concentration of A with DMF (assuming a 100% yield from step 1). -
An alkylated derivative of deoxycytidine, N⁴-(2-aminoethyl) deoxycytidine (B) was prepared from properly protected deoxyuridine via the 4-tetrazoyl derivative as described by Reese and Ubasawa, Tetrahedron Lett. 21:2265 (1984). This latter derivative was converted to B by displacement of the tetrazoyl moiety with ethylene diamine essentially as described by Sung, J. Org. Chem. 47:3623 (1982) and Maggio et al., Tetrahedron Lett. 25:3195 (1984). The corresponding 5ʹ-DMT-3ʹ-phosphoramidite N⁴-(2-N-trifluoroacetylaminoethyl) deoxycytidine was prepared by blocking the alkylamine with trifluoroacetic anhydride and then preparing the corresponding N,N-diisopropyl phosphoramidite as described (Beaucage and Caruthers, supra; McBride and Caruthers, Tetrahedron Lett. 24:245 (1983)). - Synthetic oligonucleotides were prepared by an automated phosphoramidite method as described in Warner et al., DNA 3:401 (1984). Purification was carried out according to Sanchez-Pescador and Urdea, DNA 3:339 (1984).
- The aminoethyl derivative of deoxycytidine as prepared in Example 2 was incorporated by standard coupling procedures during the oligonucleotide synthesis and the purified modified oligonucleotides were used for incorporation of a fluorescein label as follows. To a dried sample (3-5 OD 260 units) of the aminoethyl deoxycytidine containing oligomer were added 50 µl of DMF and 25 µl of the 0.M2 stock solution of A described above. After 18 h at room temperature, the solution was partially purified by Sephadex G-10 chromatography eluted with water, dried and further purified by polyacrylamide gel, as above.
- Using the probes containing aminoethylcytidine as prepared in the previous example, biotin labeling was achieved as follows. The oligonucleotide (3-5 OD 260 units) was taken up in 50 µl 0.M1 sodium phosphate, pH 7.0 and 50 µl of DMF to which 100 µl of a DMF solution containing 1 mg of a "long chain" N-hydroxysuccinimidyl biotin (Pierce Chemical) was added. After 18 h at room temperature, the biotinylated probe was purified as described for the fluorescein labeled probe.
- Fragment BʹC (a synthetic 50mer) was 5ʹ-phosphorylated with T4-polynucleotide kinase and ATP using standard conditions. After gel purification as described above, the oligonucleotide was dried by evacuation.
- Hydroxylated latex (1Omg; 0.8µ; Pandex Laboratories) was washed with DMSO, then three portions of 40mM MES (morpholinoethanesulfonic acid), pH 6.0 by centrifugation. 1500pmoles of 5ʹ-phosphorylated fragment BʹC was taken up in 90ml of 40mM MES and added to the washed support. A solution was prepared to contain 100mg of EDAC in 100ml of MES. After adding 5µl of the EDAC solution and mixing, the reaction mixture was evaporated until 30µl total remained. The mixture was left at 37°C for 18h, then centrifuged for 2min at 12,000rpm. The supernatant was discarded. The latex was suspended in 30ml of DMSO, vortexed, 100µl of water was added, the mixture vortexed for 2min and the supernatant was discarded after centrifugation. This washing process was repeated twice. The support was then washed three times with 100ml portions of 4xSSC, H₂O, then H₂O at 37°C for 15min (yield 20 picomoles fragment BʹC per mg of latex).
- A pBR322 clone containing the entire HBV genome (Valenzuela et al., Animal Virus Genetics, R. Jaenisch, B. Fields and C.F. Fox, Eds. (Academic Press: New York) pp. 57-70 (1980)) was cut with BglII and used as the analyte nucleic acid. Analyte in 10ml of formamide containing 6 picomoles of the labeling and capturing probe sets was heated to 95°C for 10min and cooled to room temperature. To this mixture, 60µl of water, 20µl of 20xSSC, 10ml of 1% NP40 and 2µl (10µg) of polyA are added, vortexed and incubated at 37°C for 1h.
- The solid supported DNA probes (8 picomoles 400vg) is added and incubated for an additional 1.5h. The mixture is centrifuged at 12,000rpm for 2min and the supernatant discarded. The support is washed once by vortexing the pellet into solution with 100ml of 4xSSC, followed by centrifugation. To the washed beads are added a mixture of 4ml of 20xSSC, 2µl of 1% NP40, 1µl (5µg) polyA, 13µl of water and 6 picomoles of fluorescein labeled probe. After incubation at 37°C for 30min, the beads are transferred to a Pandex filter plate, washed four times with 100ml of 4xSSC by vacuum filtration on the O.2µ cellulose acetate membrane of the plate. The sample is vacuumed to dryness and read on the fluorescein channel A(λexcitation-485; λemission-525) of the Pandex screen machine.
- Analyte was mixed and incubated with the labeling and capturing probes as above. Biotin labeled probe (12 picomoles) in 5µl H₂O was then added, vortexed and incubated at 37°C for 30min. To the mixture, 20ml of a 0.25% (w/v) 0.8µ avidin latex (Pandex Laboratories) in 1xPBS is added and incubated at 37°C for 1h. The mixture is washed, incubated with fluorescein probe, washed and read on the Pandex screen machine as described above.
- The HBV plasmid was sonicated to an average size of 500bp. The denaturation and hybridization were carried out as above except that 30 picomoles of labeling and capturing probes were used and a 5h annealing was employed. After incubation with 30 picomoles of biotinylated probe (2h), 50µl of 0.25% avidin beads were added and incubated (1.5h). A fluorescein probe was added and incubation was carried out for 1h followed by washing and reading on the Screen Machine as described above.
- It is evident from the above results that a highly specific sensitive assay for specific nucleic acid sequence is provided. Reagents can be readily prepared to the sequence of interest and with a few simple manipulative steps, the presence or absence of a sequence in a sample determined. The method is versatile in permitting a wide variety of labels which can be readily determined by conventional equipment. Probes can be synthesized to the desired length and easily linked to the label or a support. Universal sequences can be prepared for the label and binding to the support. Various protocols may be employed where more or less rigorous removal of background interference is achieved depending upon the requirements of the assay.
-
To 2-Deoxyuridine (10 g, 44 mmole) dried by coevaporation of pyridine and suspended in pyridine (100 ml) was added 18.4 g (54 mmole) 4,4ʹ-dimethoxytrityl chloride (DMT-Cl). The reaction was allowed to proceed for 18 h at room temperature, and 100 ml methanol was added to deactivate excess DMT-Cl. Most of the pyridine was then removed in vacuo, and the residue, dissolved in 500 ml ethyl acetate, was washed with saturated aqueous NaHCO₃ (3x500 ml). The organic phase was dried over solid Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel to give 18.0 g (77%) of 5ʹ-dimethoxytrityl-2ʹ-deoxyuridine (C). -
To 18 g (34 mmole) of C in 200 ml DMF was added imidazole (5.8 g, 85 mmole) with rapid stirring to assure complete dissolution. t-Butyldimethylsilyl chloride (7.65 g, 51 mmole) dissolved in a small volume of DMF was added dropwise with stirring and the reaction was allowed to proceed in the dark for 18 h at room temperature. The reaction mixture was diluted with ethyl acetate (250 ml) and extracted with NaHCO₃ (3x250 ml). The organic phase was dried over Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel to give 15.0 g (68% yield) of 5ʹ-O-(4,4ʹ-dimethoxytrityl-3ʹ-t-butyldimethylsilyl-2ʹ-deoxyuridine (D). -
To 15.0 g (23 mmole) of D, dried by coevaporation of pyridine and dissolved in pyridine (50 ml) was added diphenylphosphate (2.9 g, 11.5 mmole) dissolved in pyridine (5 ml). 1-(Mesitylene-2-sulfonyl)-tetrazole (MS-tet) (15.5g, 61.5 mmole) dissolved in pyridine (45 ml) was added and the reaction mixture allowed to proceed in the dark for 18 h at room temperature. To the dark brown reaction mixture was added 25 ml water. After 30 min, the product was concentrated under reduced pressure. The residue was dissolved in 250 ml methylene chloride, washed with an aqueous NaHCO₃ solution (3x250 ml), dried over Na₂SO₄, and the solvent was removed under reduced pressure in the presence of toluene. The residue was purified by flash chromatography on silica gel to give 10.0 g (62%) of 4-(1,2,3,4-Tetrazol-1-yl)-[5ʹ-(4,4ʹ-dimethoxytrityl)-3ʹ-t-butyldimethylsilyl-β-D-2ʹ-deoxy-ribosyl]-pyridine-2(1H)-one (E). -
To a solution of ethylene diamine (9.3 ml, 143 mmole) in dioxane (100 ml) cooled to 5°C was added E (10.0 g, 14.3 mmole) and left for one hour. The solvent was removed at reduced pressure and the residue was coevaporated with toluene to remove excess ethylene diamine. The product was purified by chromatography on a silica gel column, eluted with 12-20% methanol in methylene chloride to give 7.15 g (75%) of 4-N-(2-aminoethyl-5ʹ-dimethoxytrityl-3ʹ-t-butyldimethylsilyl-2ʹ-deoxycytidine (F). The product was shown to react positively with ninhydrin, confirming the presence of a free amine moiety. -
To a solution of F (6.5 g, 9.6 mmole) in pyridine (50 ml) was added N-FMOC-6-aminocaproic acid (4.26 g, 12 mmole) (FMOC represented by structure H) and DDC (2.96 g, 14.4 mmole). After 3 h, the reaction was complete as judged by tlc (silica in 10% methanol/methylene chloride). Pyridine was removed at reduced pressure. The residue was extracted with ethyl acetate, insoluble dicyclohexylurea (DCHU) filtered off and the solvent removed. The product was isolated by silica gel chromatography eluted with 4% methanol in methylene chloride affording 7.3 g (70%) of N⁴-(N-FMOC-6-aminocaproyl-2-amino-ethyl)-5ʹ-dimethyltrityl-3ʹ-t-butyldimethylsilyl-2ʹ-deoxycytidine (G). -
A solution of tetrabutylammonium fluoride (15 mmole, 15 ml of a 1M solution in THF) and aqueous HF (1.05 ml of a 50% aqueous solution) were mixed and dried by coevaporation of pyridine. The residue was dissolved in pyridine (15 ml) and added to G (7.2 g, 7.3 mmole) which was dissolved by sonication. After 18 hours at 4°C the reaction mixture was diluted with 200 ml methylene chloride. Concentrated aqueous NaHCO₃ was carefully added followed by solid NaHCO₃, added gradually so as to neutralize the HF/pyridine. After drying over Na₂SO₄, the organic phase was concentrated to an oil, which was subjected to silica gel chromatography. The product N⁴-(N-FMOC-6-amino caproyl-2-aminoethyl)-5ʹ-dimethoxytrityl-ʹ-deoxycytidine (I) was eluted with 5-6% methanol in methylene chloride to give an 86% yield (6.0 g). -
To 5.1 g (5.7 mmole) of I in methylene chloride containing (diisopropylethylamine) was added
(chloro-N,N-diisopropylaminomethoxy phosphine, 1,3 ml [1.2 eq.], K) at 0°C under argon. After 1 hr, ethyl acetate (200 ml) was added and washed with 80% saturated aqueous sodium chloride; after drying of the organic phase over Na₂SO₄, the product in methylene chloride was added dropwise to hexane at -40°C to precipitate 4.43 g (75%) of J. - Sequence 1 (5ʹ-[LCA]CTGAACGTTCAACCAGTTCA-3ʹ) where LCA = N⁴ (6-aminocaproyl-2-aminoethyl)-deoxy cytidine) was synthesized chemically and purified as described elsewhere (Warner, et al. (1984)
DNA 3, 401). To 10 OD 260 units dissolved in 50 µl of water were added 10 µl of 1.0 M sodium borate, pH 9.3, and 500 µl of distilled dimethylformamide containing 20 mg of p-phenylene diisothiocyanate. The solution was vortexed and set for 2 hr at room temperature in the dark. Approximately 3 ml of n-butanol was then added. After vortexing, adding 3 ml of water, and vortexing again, the tube was centrifuged and the yellowish upper layer discarded. The extraction process was repeated with subsequent n-butanol additions until an final volume of approximately 50 µl was obtained. The butanol was removed by evacuation, then 10 mg of HRP in 200 µl of 0.1 M borate, pH 9.3, was added. The mixture was vortexed, then set at room temperature overnight in the dark. - Separation of the HRP-DNA conjugate from free enzyme and DNA was achieved on a 7% polyacrylamide gel. The 250 µl reaction mixture was quenched with 100 µl of 25% glycerol, 0.5% SDS, 0.5% bromophenol blue, 2.5 mM EDTA. The solution was then distributed into 10 lanes of a 20 x 20 0.15 cm gel and run at 60 mAmps under standard conditions (Maxam, A., and Gilbert, W., (1980) Methods in Enzymol 65, 499-560) until the bromophenol blue was about 2/3 down the gel. The gels were set on Baker F-254 silica 60 plates that had been covered with Saran Wrap (Dow) and examined with a handheld UV-short wavelength lamp held above. Pictures of the UV-shadowed bands were taken with a Polaroid MP-4 camera system fitted with a Kodak No. 59 green filter, after which the bands were cut out with a razor blade. The bands were put into a 10-ml Bio-Rad polypropylene econo-columns to which 3 ml of 0.1 M sodium phosphate, pH 7.5, was added, then set at room temperature overnight.
- The contents of the column were filtered through the frit at the column bottom into an Amicon Centricon microconcentrator that had been washed twice with distilled water. The HRP-DNA conjugate was then concentrated by centrifugation at 3500 rpm and washed twice with 1x PBS also by centrifugation. The final solution was then stored at 4°C.
- Biotin labeled probe (Bʹ; 1000 pmoles in 66.7 µl of water) was combined with 5 ml of a 0.25 % (w/v) solution of 0.8 µ avidin beads (Pandex laboratories), 1 ml of 20x SSC, 0.5 ml of 1% NP40 and 0.6 ml of 1 mg/ml polyA. After 1 h at 37°C, the beads were washed twice by centrifugation with 4x SSC, 0.1% NP40 then stored in 2.5 ml of this solution. The HBV analyte (described above) in 3 µl water was diluted into 10 µl of 4x SSC, 1% SDS, 0.5 M NaOH and 1.5 pmoles of the labeling and capturing probe sets. The mixture was heated to 95°C for 10 min., cooled on ice and neutralized with 5 µl of 1 M acetic acid, then 10 µl of the biotin probe beads were added and the solution was incubated at 37°C for 1 h.
- The beads were washed twice by centrifugation with 4x SSC, 0.1% NP40, then taken up in 50 µl of 0.1% NP40, 1 mg/ml polyA, 10 mg/ml BSA, 1X PBS containing 1 pmole of HRP-DNA conjugate and set a 37°C for 1 h. The beads were washed with 0.1% NP40, 1X PBS three times then transferred in 50 µl to a microtiter dish. To each well, 50 µl of fresh OPD solution (98 mg OPD (O-phenylenediamine), 20 µl of 30% H₂O₂ in 10 ml of 50 mM sodium citrate pH 5.0) was added, mixed and set 5 min. at 37°C. The absorbances were recorded on a microtiter plate reader. Control hybridizations contained no HBV analyte.
Claims (8)
- An assay method for detecting a nucleic acid sequence in a sample, employing two sets of reagents: a first labeling set; and a second capturing set, said method comprising:
combining in a liquid medium under binding conditions for complementary pairs, said sample containing analyte in single-stranded form, members of said labeling set of reagents comprising:(a) a plurality of labeling nucleic acid probes, different probes having a different first analyte complementary sequence and a first noncomplementary region comprising a label reagent recognition sequence, said first analyte complementary sequence having a nucleic acid sequence about 15 to 100 nucleotides in length and said first noncomplementary region optionally being at most about 5 kb in length; and(b) a labeling reagent having a nucleic acid sequence complementary to said label reagent recognition sequence, wherein said label provides, directly or indirectly, a detectable signal; and
members of said second capturing set of reagents comprising:(c) a plurality of capturing nucleic acid probes, different probes having a different second analyte complementary sequence and a second noncomplementary region comprising a capturing reagent recognition sequence, said second analyte complementary sequence having a nucleic acid sequence about 15 to about 100 nucleotides in length and said second noncomplementary region optionally being at most about 5kb in length; and(d) a capturing reagent having a nucleic acid sequence complementary to said capturing reagent recognition sequence and capable of binding, directly or indirectly, with a separation means;
separating said label into a bound phase and an unbound phase by means of said separation means; and
detecting the amount of bound or unbound label as determinative of the presence of said analyte. - A method according to claim 1, wherein said nucleic acid sequence complementary to said capturing reagent recognition sequence is bound directly to said separation means, and said analyte, (a), (b), and (c) are combined together for a time sufficient for nucleic acid complexes to form, followed by the addition of said nucleic acid sequence complementary to said capturing reagent recognition sequence bound to said separation means.
- A method according to claim 1, wherein said separation means is a solid support and wherein said capturing reagent is bound thereto.
- An assay method for detecting a nucleic acid sequence in a sample, employing two sets of reagents: a first labeling set; and a second capturing set, said method comprising:
combining in a liquid medium under binding conditions for complementary nucleic acid sequences, said sample containing analyte in single-stranded form, members of said labeling set of reagents comprising:(a) a plurality of labeling nucleic acid probes including a fluorescer or enzyme label, different probes having a different first analyte complementary sequence and a first noncomplementary region comprising a label reagent recognition sequence, said first analyte complementary sequence having a nucleic acid sequence about 15 to 100 nucleotides in length and said first noncomplementary region optionally being at most about 5kb in length; and(b) a labeling reagent having a nucleic acid sequence complementary to said label reagent recognition sequence; and
members of said second capturing set of reagents comprising:(c) a plurality of capturing nucleic acid probes, different probes having a different second analyte complementary sequence and a second noncomplementary region comprising a capturing reagent recognition sequence, said second analyte complementary sequence having a nucleic acid sequence about 15 to about 100 nucleotides in length and said noncomplementary region optionally being at most about 5kb in length; and(d) a capturing reagent having a nucleic acid sequence complementary to said capturing reagent recognition sequence;
binding said capturing reagent to a solid support through a specific binding pair comprising a hapten and an antibody, either during or after said combining;
separating said label into a bound phase and an unbound phase by means of said solid support; and
detecting the amount of bound or unbound label as determinative of the presence of said analyte. - A kit for detecting a nucleic acid analyte comprising:(1) members of a labeling set of reagents comprising:(a) a plurality of labeling nucleic acid probes, different probes having a different first analyte complementary sequence and a first noncomplementary region comprising a label reagent recognition sequence, said first analyte complementary sequence having a nucleic acid sequence about 15 to 100 nucleotides in length and said first noncomplementary region optionally being at most about 5 kb in length; and(b) a labeling reagent having a nucleic acid sequence complementary to said label reagent recognition sequence, wherein said label provides, directly or indirectly, a detectable signal; and(2) members of a second capturing set of reagents comprising:(c) a plurality of capturing nucleic acid probes, different probes having a different second analyte complementary sequence and a second noncomplementary region comprising a second capturing reagent recognition sequence having a nucleic acid sequence about 15 to about 100 nucleotides in length and said second noncomplementary region optionally being at most about 5 kb in length;(d) a capturing reagent having a nucleic acid sequence complementary to said capturing reagent recognition sequence a first member of a specific binding pair conjugate; and(e) support means conjugated to a second complementary member of said specific binding pair.
- The use of the following in the manufacture of a kit for detecting a nucleic acid sequence:(1) members of a labeling set of reagents comprising:(a) a plurality of labeling nucleic acid probes, different probes having a different first analyte complementary sequence and a first noncomplementary region comprising a label reagent recognition sequence, said first analyte complementary sequence having a nucleic acid sequence about 15 to 100 nucleotides in length and said first noncomplementary region optionally being at most about 5 kb in length; and(b) a labeling reagent having a nucleic acid sequence complementary to said label reagent recognition sequence, wherein said label provides, directly or indirectly, a detectable signal; and(2) members of a second capturing set of reagents comprising:(c) a plurality of capturing nucleic acid probes, different probes having a different second analyte complementary sequence and a second noncomplementary region comprising a second capturing reagent recognition sequence having a nucleic acid sequence about 15 to about 100 nucleotides in length and said second noncomplementary region optionally being at most about 5kb in length;(d) a capturing reagent having a nucleic acid sequence complementary to said second recognition sequence and containing a first member of a specific binding pair conjugate; and(e) support means conjugated to a second complementary member of said specific binding pair.
- The use of a polynucleotide probe in an assay method according to any one of claims 1 to 4, wherein the probe has at least two nucleotides, at least one of which is given by the structure
- The use according to claim 6 wherein a polynucleotide probe as defined in claim 7 is employed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90121584A EP0423839B1 (en) | 1985-12-11 | 1986-12-10 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/807,624 US4868105A (en) | 1985-12-11 | 1985-12-11 | Solution phase nucleic acid sandwich assay |
US807624 | 1985-12-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90121584A Division EP0423839B1 (en) | 1985-12-11 | 1986-12-10 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay |
EP90121584.8 Division-Into | 1990-11-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0225807A2 EP0225807A2 (en) | 1987-06-16 |
EP0225807A3 EP0225807A3 (en) | 1988-09-07 |
EP0225807B1 true EP0225807B1 (en) | 1994-10-19 |
Family
ID=25196815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90121584A Expired - Lifetime EP0423839B1 (en) | 1985-12-11 | 1986-12-10 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay |
EP86309622A Expired - Lifetime EP0225807B1 (en) | 1985-12-11 | 1986-12-10 | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90121584A Expired - Lifetime EP0423839B1 (en) | 1985-12-11 | 1986-12-10 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay |
Country Status (7)
Country | Link |
---|---|
US (1) | US4868105A (en) |
EP (2) | EP0423839B1 (en) |
JP (2) | JP2655569B2 (en) |
AT (2) | ATE113078T1 (en) |
CA (2) | CA1303033C (en) |
DE (2) | DE3650103T2 (en) |
ES (2) | ES2160569T3 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989003891A1 (en) * | 1987-10-15 | 1989-05-05 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
EP0318255A2 (en) * | 1987-11-23 | 1989-05-31 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Cuvette |
WO1990008156A1 (en) * | 1989-01-20 | 1990-07-26 | Cis Bio International | Derivatives of polyhydroxylated molecules for introducing at least one ramification in an oligonucleotide |
WO1990013667A1 (en) * | 1989-04-18 | 1990-11-15 | Chiron Corporation | Improved amplified nucleic acid hybridization assays for hbv |
EP0421469A2 (en) * | 1989-10-06 | 1991-04-10 | Canon Kabushiki Kaisha | Method for separating nucleic acid |
WO1991006674A1 (en) * | 1989-11-06 | 1991-05-16 | Scotgen Ltd. | Method and device for the detection of antibiotic resistance |
WO1991008307A1 (en) * | 1989-12-04 | 1991-06-13 | Microprobe Corporation | Enhanced capture of target nucleic acid by the use of oligonucleotides covalently attached to polymers |
WO1991017442A1 (en) * | 1990-05-04 | 1991-11-14 | Chiron Corporation | Protein-nucleic acid probes and immunoassays using same |
EP0523557A1 (en) * | 1991-07-16 | 1993-01-20 | Roche Diagnostics GmbH | Immobilisation of nucleic acids |
EP0541693A1 (en) * | 1990-07-27 | 1993-05-19 | Chiron Corporation | Large comb-type branched polynucleotides |
US5545730A (en) * | 1984-10-16 | 1996-08-13 | Chiron Corporation | Multifunctional nucleic acid monomer |
US5571670A (en) * | 1987-10-15 | 1996-11-05 | Chiron Corporation | Nucleic acid probes useful in detecting Chlamydia trachomatis and amplified nucleic acid hybridization assays using same |
US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
US5656731A (en) * | 1987-10-15 | 1997-08-12 | Chiron Corporation | Nucleic acid-amplified immunoassay probes |
US5681702A (en) * | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5817786A (en) * | 1983-02-22 | 1998-10-06 | Molecular Biosystems, Inc. | Single-stranded labelled oligonucleotides of preselected sequences |
US5876928A (en) * | 1978-04-13 | 1999-03-02 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
US6040193A (en) | 1991-11-22 | 2000-03-21 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
USRE37891E1 (en) * | 1986-10-23 | 2002-10-22 | Vysis, Inc. | Target and background capture methods with amplification for affinity assays |
US7972579B2 (en) | 2003-07-04 | 2011-07-05 | F. Hoffmann-La Roche Ag | Device for the automatic opening and closing of reaction vessels |
US9738727B2 (en) | 2011-10-14 | 2017-08-22 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use |
US11512143B2 (en) | 2015-10-30 | 2022-11-29 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use thereof |
Families Citing this family (284)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US7220854B1 (en) | 1982-06-23 | 2007-05-22 | Enzo Life Sciences, Inc. C/O Enzo Biochem, Inc. | Sugar moiety labeled nucleotide, and an oligo- or polynucleotide, and other compositions comprising such sugar moiety labeled nucleotides |
US5192683A (en) * | 1987-02-19 | 1993-03-09 | The Royal Institution For The Advancement Of Learning (Mcgill University) | Monoclonal antibodies to cruciform DNA structure |
JP2565552B2 (en) * | 1987-10-15 | 1996-12-18 | カイロン コーポレイション | Nucleic acid multimer and amplified nucleic acid hybridization analysis method using the same |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
DE3882040T2 (en) * | 1987-12-01 | 1993-09-30 | Biotope Inc | METHOD AND DEVICES FOR CARRYING OUT EXAMINATIONS. |
ATE133714T1 (en) | 1988-09-29 | 1996-02-15 | Chiron Corp | POLYNUCLEOTIDE DETERMINATION WITH SELECTABLE CLEAVAGE SITES |
JP2615200B2 (en) * | 1989-05-31 | 1997-05-28 | 株式会社リコー | Reversible thermosensitive recording material |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
DE69032847T2 (en) * | 1989-06-30 | 1999-05-12 | Chiron Corp | Hydrophobic nucleic acid probe |
JP3156200B2 (en) | 1989-09-15 | 2001-04-16 | 国立予防衛生研究所長 | New HCV isolate |
CA2070632A1 (en) | 1990-01-10 | 1991-07-11 | Bayer Corporation | Use of dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
US5629153A (en) * | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
US6114513A (en) * | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5200314A (en) * | 1990-03-23 | 1993-04-06 | Chiron Corporation | Polynucleotide capture assay employing in vitro amplification |
CA2039517C (en) * | 1990-04-03 | 2006-11-07 | David Segev | Dna probe signal amplification |
US5556751A (en) * | 1991-04-25 | 1996-09-17 | Amoco Corporation | Selective amplification system using Q-β replicase |
US6190864B1 (en) | 1991-05-08 | 2001-02-20 | Chiron Corporation | HCV genomic sequences for diagnostics and therapeutics |
WO1993003184A1 (en) * | 1991-08-09 | 1993-02-18 | Mccann Associates, Inc. | Method for detecting lyme disease and composition |
JP2562862B2 (en) * | 1991-08-28 | 1996-12-11 | ベーリンガー・マンハイム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Functional carriers for simultaneous synthesis and direct labeling of oligonucleotides as primers for template-dependent enzymatic nucleic acid synthesis |
US5556961A (en) * | 1991-11-15 | 1996-09-17 | Foote; Robert S. | Nucleosides with 5'-O-photolabile protecting groups |
WO1993013226A1 (en) * | 1991-12-23 | 1993-07-08 | Chiron Corporation | Hav probes for use in solution phase sandwich hybridization assays |
EP0618924B1 (en) * | 1991-12-23 | 2001-02-14 | Bayer Corporation | Hbv amplifier probes for use in solution phase sandwich hybridization assays |
US5747244A (en) * | 1991-12-23 | 1998-05-05 | Chiron Corporation | Nucleic acid probes immobilized on polystyrene surfaces |
WO1993013221A1 (en) * | 1991-12-23 | 1993-07-08 | Chiron Corporation | Chlamydiae probes for use in solution phase sandwich hybridization assays |
DE69233630T2 (en) | 1991-12-23 | 2007-05-31 | Chiron Corp., Emeryville | Sets of HIV probes for use in solution phase sandwich hydride assays |
CA2125144A1 (en) | 1991-12-23 | 1993-07-08 | Chiron Diagnostics Corporation | Htlv-1 probes for use in solution phase sandwich hybridization assays |
EP0571087A1 (en) * | 1992-05-18 | 1993-11-24 | Rohm And Haas Company | Cleavable phosphoramidites |
US5543292A (en) * | 1992-06-16 | 1996-08-06 | Hitachi, Ltd. | Process for the measurement of nucleic acids |
EP0672185A4 (en) * | 1992-07-17 | 1997-04-23 | Aprogenex Inc | Nucleic acid probes and uses thereof to detect double-stranded nucleic acids. |
US5329461A (en) * | 1992-07-23 | 1994-07-12 | Acrogen, Inc. | Digital analyte detection system |
JP3645904B2 (en) | 1993-05-10 | 2005-05-11 | カイロン コーポレイション | Method for classification of hepatitis C virus type and reagent used therefor |
EP0701629B1 (en) * | 1993-05-28 | 2006-08-02 | Mount Sinai School of Medicine of New York University | Bc200 rna, probes therefor and use thereof |
US5382512A (en) * | 1993-08-23 | 1995-01-17 | Chiron Corporation | Assay device with captured particle reagent |
FR2710075B1 (en) * | 1993-09-15 | 1995-10-27 | Bio Merieux | Reagent and method for the detection of a nucleotide sequence with signal amplification. |
US5681697A (en) * | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US7323298B1 (en) * | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
US6306657B1 (en) * | 1994-06-28 | 2001-10-23 | Kalyx Biosciences, Inc. | Polynucleotide probe and kit for amplifying signal detection in hybridization assays |
AU686004B2 (en) | 1994-08-12 | 1998-01-29 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
PT699754E (en) | 1994-08-12 | 2001-04-30 | Us Health | METHOD FOR DIAGNOSING A PREDISPOSITION FOR CANCER OF BREAST AND OVARY |
US5580731A (en) * | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US8236493B2 (en) | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US5747248A (en) * | 1994-12-05 | 1998-05-05 | Chiron Corporation | Discontinuous probe design using hybritope mapping |
US20030104361A1 (en) * | 1997-09-29 | 2003-06-05 | Susan Weininger | Method of detection of nucleic acids with a specific sequence composition |
US5871902A (en) * | 1994-12-09 | 1999-02-16 | The Gene Pool, Inc. | Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids |
US5801155A (en) * | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
US6312894B1 (en) | 1995-04-03 | 2001-11-06 | Epoch Pharmaceuticals, Inc. | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders |
US5853974A (en) * | 1995-06-07 | 1998-12-29 | Chiron Corporation | Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates |
US5780227A (en) * | 1995-06-07 | 1998-07-14 | Sheridan; Patrick J. | Oligonucleotide probe conjugated to a purified hydrophilic alkaline phosphatase and uses thereof |
FR2737502B1 (en) | 1995-07-31 | 1997-10-24 | Genset Sa | NUCLEIC ACID DETECTION METHOD USING NUCLEOTIDE PROBES ALLOWING BOTH SPECIFIC CAPTURE AND DETECTION |
US6017700A (en) * | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
JP3455228B2 (en) | 1995-12-18 | 2003-10-14 | ミリアド・ジェネティックス・インコーポレイテッド | Chromosome 13 linkage-breast cancer susceptibility gene |
NZ330743A (en) | 1995-12-22 | 1999-07-29 | Univ Utah Res Found | A long qt syndrome gene which encodes kvlqt1 and its association with mink |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
US5824478A (en) * | 1996-04-30 | 1998-10-20 | Vysis, Inc. | Diagnostic methods and probes |
US6103535A (en) * | 1996-05-31 | 2000-08-15 | University Of Maryland | Optical fiber evanescent field excited fluorosensor and method of manufacture |
US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
CA2276462C (en) * | 1996-12-31 | 2007-06-12 | Genometrix Incorporated | Multiplexed molecular analysis system apparatus and method |
JPH10253632A (en) * | 1997-03-10 | 1998-09-25 | Nissui Pharm Co Ltd | Method, kit and device for analysis |
DE69836012T2 (en) | 1997-05-02 | 2007-04-05 | Gen-Probe Inc., San Diego | TWO-STEP HYBRIDIZATION AND INJECTION OF A POLYNUCLEOTIDE |
US6534273B2 (en) | 1997-05-02 | 2003-03-18 | Gen-Probe Incorporated | Two-step hybridization and capture of a polynucleotide |
US5939261A (en) * | 1997-06-24 | 1999-08-17 | Sarnoff Corporation | Method for capturing a nucleic acid |
GB9718921D0 (en) * | 1997-09-05 | 1997-11-12 | Brax Genomics Ltd | Catalytically generated mass labels |
ATE299946T1 (en) * | 1997-12-12 | 2005-08-15 | Digene Corp | EVALUATION OF HUMAN PAPILLOMA VIRUS-RELATED DISEASE |
US6458533B1 (en) | 1997-12-19 | 2002-10-01 | High Throughput Genomics, Inc. | High throughput assay system for monitoring ESTs |
US20030096232A1 (en) * | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
US20100105572A1 (en) * | 1997-12-19 | 2010-04-29 | Kris Richard M | High throughput assay system |
US20030039967A1 (en) * | 1997-12-19 | 2003-02-27 | Kris Richard M. | High throughput assay system using mass spectrometry |
US6232066B1 (en) | 1997-12-19 | 2001-05-15 | Neogen, Inc. | High throughput assay system |
US6238869B1 (en) | 1997-12-19 | 2001-05-29 | High Throughput Genomics, Inc. | High throughput assay system |
GB9805935D0 (en) * | 1998-03-19 | 1998-05-13 | Ciba Geigy Ag | Organic compounds |
US7045610B2 (en) * | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
US6949367B1 (en) | 1998-04-03 | 2005-09-27 | Epoch Pharmaceuticals, Inc. | Modified oligonucleotides for mismatch discrimination |
US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
US7715989B2 (en) * | 1998-04-03 | 2010-05-11 | Elitech Holding B.V. | Systems and methods for predicting oligonucleotide melting temperature (TmS) |
US6127121A (en) * | 1998-04-03 | 2000-10-03 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination |
US6183957B1 (en) | 1998-04-16 | 2001-02-06 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria |
CA2330732A1 (en) * | 1998-06-19 | 1999-12-23 | Mosaic Technologies | Detection of non-viral organisms with srp rna |
US6306643B1 (en) * | 1998-08-24 | 2001-10-23 | Affymetrix, Inc. | Methods of using an array of pooled probes in genetic analysis |
EP2306195A3 (en) | 1998-09-18 | 2012-04-25 | Massachusetts Institute of Technology | Biological applications of semiconductor nanocrystals |
US6326149B1 (en) | 1998-11-03 | 2001-12-04 | Sarnoff Corporation | Method for controlled electrostatic adherent deposition of particles on a substrate |
US6432642B1 (en) * | 1999-01-15 | 2002-08-13 | Pe Corporation (Ny) | Binary probe and clamp composition and methods for a target hybridization detection |
JP2002544488A (en) * | 1999-05-07 | 2002-12-24 | クアンタム ドット コーポレイション | Methods for detecting analytes using semiconductor nanocrystals |
US6750357B1 (en) | 1999-06-25 | 2004-06-15 | Syngen, Inc. | Rhodamine-based fluorophores useful as labeling reagents |
US6465183B2 (en) * | 1999-07-01 | 2002-10-15 | Agilent Technologies, Inc. | Multidentate arrays |
US7122303B2 (en) | 1999-09-17 | 2006-10-17 | Agilent Technologies, Inc. | Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same |
US7078167B2 (en) * | 1999-09-17 | 2006-07-18 | Agilent Technologies, Inc. | Arrays having background features and methods for using the same |
US6428957B1 (en) | 1999-11-08 | 2002-08-06 | Agilent Technologies, Inc. | Systems tools and methods of assaying biological materials using spatially-addressable arrays |
US20040081959A9 (en) * | 1999-12-08 | 2004-04-29 | Epoch Biosciences, Inc. | Fluorescent quenching detection reagents and methods |
US7205105B2 (en) * | 1999-12-08 | 2007-04-17 | Epoch Biosciences, Inc. | Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis |
US6727356B1 (en) | 1999-12-08 | 2004-04-27 | Epoch Pharmaceuticals, Inc. | Fluorescent quenching detection reagents and methods |
US6902891B2 (en) | 1999-12-17 | 2005-06-07 | Bio Merieux | Process for labeling a nucleic acid |
US6489114B2 (en) | 1999-12-17 | 2002-12-03 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby |
US20020009728A1 (en) * | 2000-01-18 | 2002-01-24 | Quantum Dot Corporation | Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization |
US6235483B1 (en) | 2000-01-31 | 2001-05-22 | Agilent Technologies, Inc. | Methods and kits for indirect labeling of nucleic acids |
ES2391213T3 (en) | 2000-03-01 | 2012-11-22 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
EP1944310A3 (en) | 2000-03-01 | 2008-08-06 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
ES2287134T3 (en) * | 2000-06-02 | 2007-12-16 | Bayer Corporation | PROCEDURE FOR THE DETECTION AND LOCATION OF GENES IN SITU USING HYBRIDIZATION OF RAMIFIED DNA. |
US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
US7601497B2 (en) * | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
GB0016833D0 (en) * | 2000-07-07 | 2000-08-30 | Lee Helen | Improved dipstick assays (2) |
AU2001269292A1 (en) * | 2000-07-07 | 2002-01-21 | Helen Lee | Improved stability of hybridisation interactions in dipstick assays |
GB0016836D0 (en) * | 2000-07-07 | 2000-08-30 | Lee Helen | Improved dipstick assays (1) |
CA2419649C (en) | 2000-09-01 | 2011-03-08 | Gen-Probe Incorporated | Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations |
US20040185464A1 (en) * | 2000-09-15 | 2004-09-23 | Kris Richard M. | High throughput assay system |
US6870045B2 (en) | 2000-10-23 | 2005-03-22 | Gen-Probe Incorporated | Kits for detecting HIV-2 |
EP1390530A2 (en) * | 2001-01-05 | 2004-02-25 | Genomicfx, Inc. | Method for relative quantification of attached nucleic acids |
US7018795B2 (en) * | 2001-03-23 | 2006-03-28 | Fuji Photo Film Co., Ltd. | Hybridization probe and target nucleic acid detecting kit, target nucleic acid detecting apparatus and target nucleic acid detecting method using the same |
US7077982B2 (en) * | 2001-03-23 | 2006-07-18 | Fuji Photo Film Co., Ltd. | Molecular electric wire, molecular electric wire circuit using the same and process for producing the molecular electric wire circuit |
US20020168756A1 (en) * | 2001-03-23 | 2002-11-14 | Fuji Photo Film Co., Ltd. | Particle size variable reactor |
US20030003476A1 (en) * | 2001-03-23 | 2003-01-02 | Fuji Photo Film Co., Ltd. | Waste water inspecting agent and waste water inspecting apparatus using the same |
US20020168667A1 (en) * | 2001-03-23 | 2002-11-14 | Fuji Photo Film Co., Ltd. | Antigen detecting agent and antigen detecting kit, antigen detecting apparatus and antigen detecting method using the same |
US20030082571A1 (en) * | 2001-04-10 | 2003-05-01 | Kachab Edward Hanna | Linear nucleic acid and sequence therefor |
EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
EP1435520A4 (en) * | 2001-09-21 | 2005-02-02 | Takara Bio Inc | Support for ligand immobilization |
US6946245B2 (en) | 2001-12-04 | 2005-09-20 | Quest Diagnostics Investments Incorporated | Oligonucleotides and methods for detecting hepatitis C viral nucleic acids |
US20030175709A1 (en) * | 2001-12-20 | 2003-09-18 | Murphy George L. | Method and system for depleting rRNA populations |
US20030179381A1 (en) * | 2002-03-18 | 2003-09-25 | Fuji Photo Film Co., Ltd. | Sensor, color sensor and apparatus for inspection using the same |
US20040023267A1 (en) | 2002-03-21 | 2004-02-05 | Morris David W. | Novel compositions and methods in cancer |
US20030219755A1 (en) * | 2002-05-24 | 2003-11-27 | Nanibhushan Dattagupta | Compositions and methods for performing hybridization assays using target enhanced signal amplification (TESA) |
WO2003106714A1 (en) | 2002-06-14 | 2003-12-24 | Gen-Probe Incorporated | Compositions and methods for detecting hepatitis b virus |
EP1556325A4 (en) * | 2002-09-20 | 2007-09-19 | Integrated Dna Tech Inc | Anthraquinone quencher dyes, their methods of preparation and use |
US7115374B2 (en) | 2002-10-16 | 2006-10-03 | Gen-Probe Incorporated | Compositions and methods for detecting West Nile virus |
US7597936B2 (en) * | 2002-11-26 | 2009-10-06 | University Of Utah Research Foundation | Method of producing a pigmented composite microporous material |
JP4824312B2 (en) * | 2002-11-26 | 2011-11-30 | ユニバーシティ オブ ユタ リサーチ ファンデーション | Microporous material, analyte localization and quantification method, and analyte localization and quantification article |
JP4294946B2 (en) * | 2002-12-13 | 2009-07-15 | 富士フイルム株式会社 | Target detection apparatus, target detection method, and target detection substrate |
US7076127B2 (en) * | 2003-01-14 | 2006-07-11 | Fuji Photo Film Co., Ltd. | Optical switch and safety apparatus using the same |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
JP2007524362A (en) | 2003-02-14 | 2007-08-30 | サイグレス ディスカバリー, インコーポレイテッド | Therapeutic GPCR targets in cancer |
US20040241661A1 (en) * | 2003-05-29 | 2004-12-02 | Arindam Bhattacharjee | Pseudo single color method for array assays |
US7348146B2 (en) * | 2003-10-02 | 2008-03-25 | Epoch Biosciences, Inc. | Single nucleotide polymorphism analysis of highly polymorphic target sequences |
JP4942484B2 (en) * | 2003-10-28 | 2012-05-30 | エポック・バイオサイエンシーズ・インコーポレイテッド | Fluorescent probe for DNA detection by hybridization with improved sensitivity and low background |
US7439341B2 (en) * | 2003-11-14 | 2008-10-21 | Integrated Dna Technologies, Inc. | Fluorescence quenching azo dyes, their methods of preparation and use |
DE602004028862D1 (en) | 2003-12-19 | 2010-10-07 | Gen Probe Inc | THE NUCLEIC ACIDS OF HIV-1 AND HIV-2 |
US20050244984A1 (en) * | 2004-04-28 | 2005-11-03 | Parker Russell A | Methods and compositions for calibrating chemical array readers |
EP2402465B1 (en) | 2004-07-13 | 2014-11-19 | Gen-Probe Incorporated | Method and kit for detection of Hepatitis A virus nucleic acid |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
DK2975139T3 (en) | 2004-09-30 | 2019-12-09 | Gen Probe Inc | ASSAY TO DETECT AND QUANTIFY HIV-1 |
US20060223080A1 (en) * | 2004-11-09 | 2006-10-05 | Gen-Probe Incorporated | Compositions and methods for detecting group a streptococci |
US20060172314A1 (en) * | 2005-01-31 | 2006-08-03 | Song Min-Sun | Quantification of amplified nucleic acids |
CA2592179C (en) * | 2005-02-07 | 2012-04-03 | Gen-Probe Incorporated | Compositions and methods for detecting group b streptococci |
WO2006089154A1 (en) | 2005-02-18 | 2006-08-24 | Gen-Probe Incorporated | Sample preparation method incorporating an alkaline shock |
WO2006110314A2 (en) | 2005-03-25 | 2006-10-19 | Ambion, Inc. | Methods and compositions for depleting abundant rna transcripts |
JP2008535857A (en) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | CACNA1E in cancer diagnosis, detection and treatment |
JP2008535494A (en) | 2005-04-07 | 2008-09-04 | サグレシュ ディスカバリー, インコーポレイテッド | Cancer-related gene (PRLR) |
US8124335B2 (en) | 2005-05-06 | 2012-02-28 | Gen-Probe Incorporated | Compositions and assays to detect influenza virus A and B nucleic acids |
ES2381279T3 (en) | 2005-05-06 | 2012-05-24 | Gen-Probe Incorporated | Methods and products for capturing target nucleic acid |
US8628918B2 (en) * | 2005-05-09 | 2014-01-14 | Affymetrix, Inc. | Multiplex capture of nucleic acids |
US8632970B2 (en) | 2005-05-09 | 2014-01-21 | Affymetrix, Inc. | Multiplex capture of nucleic acids |
DE602006020715D1 (en) * | 2005-05-12 | 2011-04-28 | Affymetrix Inc | MULTIPLEX ASSAYS FOR BRANCHED DNA |
AU2006251637B2 (en) | 2005-05-20 | 2012-06-14 | Integrated Dna Technologies, Inc. | Compounds and methods for labeling oligonucleotides |
EP2711434B1 (en) | 2005-06-20 | 2016-09-14 | Advanced Cell Diagnostics, Inc. | Multiplex detection of nucleic acids |
US7927798B2 (en) * | 2005-10-05 | 2011-04-19 | Panomics, Inc. | Detection of nucleic acids from whole blood |
AU2006304721B2 (en) | 2005-10-17 | 2012-01-19 | Gen-Probe Incorporated | Compositions and methods to detect Legionella pneumophila nucleic acid |
CA2627967A1 (en) | 2005-11-10 | 2007-05-24 | Panomics, Inc. | Detection of nucleic acids through amplification of surrogate nucleic acids |
US7831417B2 (en) | 2005-11-14 | 2010-11-09 | Gen-Probe Incorporated | Parametric calibration method |
JP4858751B2 (en) * | 2005-11-30 | 2012-01-18 | 日本精機株式会社 | Magnet rotor, movable magnet type instrument having the magnet rotor, and stepping motor having the magnet rotor |
AU2007249286B2 (en) * | 2006-05-12 | 2013-06-13 | Gen-Probe Incorporated | Compositions and methods to detect enterococci nucleic acid |
BRPI0713098A2 (en) | 2006-05-22 | 2012-10-16 | Clinical Genomics Pty Ltd | method for determining the anatomical origin of an individual's large intestine-derived cell or cell population, detection method for determining the anatomical origin of an individual's large intestine-derived cell or cell population, detection system, legible storage medium by computer, nucleic acid arrangement, use of an arrangement, method for determining the onset or predisposition for the onset of a cellular abnormality or a condition distinguished by a cellular abnormality in the large intestine, diagnostic kit for assaying biological samples |
JP5635772B2 (en) | 2006-08-01 | 2014-12-03 | ジェン−プロウブ インコーポレイテッド | Method for capturing non-specific target of nucleic acid |
JP2008043332A (en) | 2006-08-17 | 2008-02-28 | Panomics Inc | Quantitative determination of nucleic acid from tissue slide |
US7492312B2 (en) * | 2006-11-14 | 2009-02-17 | Fam Adly T | Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception |
US7615351B2 (en) * | 2006-12-01 | 2009-11-10 | Panomics, Inc. | Two stage nucleic acid amplification using an amplification oligomer |
US8198027B2 (en) | 2006-12-21 | 2012-06-12 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
WO2008094370A2 (en) | 2006-12-22 | 2008-08-07 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US8114681B2 (en) * | 2007-10-05 | 2012-02-14 | Affymetrix, Inc. | Highly multiplexed particle-based assays |
CN102099485A (en) | 2007-10-23 | 2011-06-15 | 临床基因组学有限公司 | A method of diagnosing neoplasms - II |
WO2009052573A1 (en) | 2007-10-23 | 2009-04-30 | Clinical Genomics Pty. Ltd. | A method of diagnosing neoplasms |
US7595164B2 (en) * | 2007-12-26 | 2009-09-29 | Gen-Probe Incorporated | Compositions and methods to detect Candida albicans nucleic acid |
CA2721536A1 (en) | 2008-04-21 | 2009-10-29 | Gen-Probe Incorporated | Method for detecting chikungunya virus |
WO2009140374A2 (en) * | 2008-05-13 | 2009-11-19 | Gen-Probe Incorporated | Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences |
US20090298709A1 (en) * | 2008-05-28 | 2009-12-03 | Affymetrix, Inc. | Assays for determining telomere length and repeated sequence copy number |
AU2009320213B2 (en) * | 2008-10-27 | 2016-06-16 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay and system |
EP2385979B1 (en) * | 2009-01-28 | 2017-08-16 | QIAGEN Gaithersburg, Inc. | Sequence-specific large volume sample preparation method and assay |
AU2010217928B2 (en) | 2009-02-26 | 2013-06-06 | Gen-Probe Incorporated | Assay for detection of human parvovirus nucleic acid |
WO2010117817A2 (en) | 2009-03-30 | 2010-10-14 | Life Technologies Corporation | Methods for generating target specific probes for solution based capture |
AU2010242867B2 (en) * | 2009-05-01 | 2016-05-12 | Qiagen Gaithersburg, Inc. | A non-target amplification method for detection of RNA splice-forms in a sample |
CA2768768C (en) | 2009-06-23 | 2021-08-24 | Gen-Probe Incorporated | Compositions and methods for detecting nucleic acid from mollicutes |
AU2010266234B2 (en) | 2009-07-01 | 2013-07-25 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
US20120015821A1 (en) * | 2009-09-09 | 2012-01-19 | Life Technologies Corporation | Methods of Generating Gene Specific Libraries |
WO2011032124A1 (en) | 2009-09-14 | 2011-03-17 | Qiagen Gaithersburg, Inc. | Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media |
KR20120108967A (en) | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | Coiled coil and/or tether containing protein complexes and uses thereof |
US20130023433A1 (en) | 2009-09-28 | 2013-01-24 | Yuling Luo | Methods of detecting nucleic acid sequences with high specificity |
CN102725424B (en) | 2010-01-25 | 2014-07-09 | Rd生物科技公司 | Self-folding amplification of target nucleic acid |
BR112012018545A2 (en) | 2010-01-29 | 2016-05-03 | Qiagen Gaithersburg Inc | method of determining and confirming the presence of an hpv in a sample |
CA2787924A1 (en) | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
EP3040425B1 (en) | 2010-02-17 | 2019-08-28 | Gen-Probe Incorporated | Compostions and methods to detect atopobium vaginae nucleic acid |
US20120108799A1 (en) | 2010-09-07 | 2012-05-03 | Integrated Dna Technologies, Inc. | Modifications for Antisense Compounds |
US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
EP2553123B1 (en) * | 2010-03-26 | 2016-08-24 | Integrated DNA Technologies, Inc. | Methods for enhancing nucleic acid hybridization |
AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
CA3011697C (en) | 2010-04-21 | 2020-04-07 | Gen-Probe Incorporated | Compositions, methods and kits to detect herpes simplex virus nucleic acids |
JP2013528049A (en) | 2010-05-19 | 2013-07-08 | キアゲン ガイサーズバーグ アイエヌシー. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
AU2011258501B2 (en) | 2010-05-25 | 2016-07-07 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
US9234249B2 (en) | 2010-07-12 | 2016-01-12 | Gen-Probe Incorporated | Compositions and assays to detect swine H1N1 influenza A virus, seasonal H1 influenza A virus and seasonal H3 influenza A virus nucleic acids |
WO2012030856A2 (en) | 2010-08-30 | 2012-03-08 | Gen-Probe Incorporated | Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus |
EP2625297B1 (en) | 2010-10-04 | 2018-10-10 | Gen-Probe Prodesse, Inc. | Compositions, methods and kits to detect adenovirus nucleic acids |
ES2648564T3 (en) | 2010-10-21 | 2018-01-04 | Advanced Cell Diagnostics, Inc. | Ultrasensitive method for in situ detection of nucleic acids |
CN103384681B (en) | 2010-12-23 | 2018-05-18 | 霍夫曼-拉罗奇有限公司 | Bonding agent |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
EP2659269B1 (en) | 2010-12-23 | 2016-10-26 | Roche Diagniostics GmbH | Detection of a posttranslationally modified polypeptide by a bi-valent binding agent |
CN103597095B (en) | 2011-02-24 | 2016-08-17 | 奇亚根盖瑟斯堡股份有限公司 | For detecting material and the method for HPV nucleic acid |
EP2683833B1 (en) | 2011-03-10 | 2018-09-26 | Gen-Probe Incorporated | Methods for the selection and optimization of oligonucleotide tag sequences |
EP2702166B1 (en) | 2011-04-25 | 2018-06-06 | Gen-Probe Incorporated | Compositions and methods for detecting bv-associated bacterial nucleic acid |
US8679760B2 (en) * | 2011-05-03 | 2014-03-25 | National Cheng Kung University | Biomarker and method for evaluating risk of proliferation, invasion, or metastasis of cancer |
US9752201B2 (en) | 2011-07-15 | 2017-09-05 | Gen-Probe Incorporated | Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays |
EP3722423A1 (en) | 2011-08-05 | 2020-10-14 | Illumina, Inc. | Functionalization and purification of molecules by reversible group exchange |
WO2013036928A1 (en) | 2011-09-08 | 2013-03-14 | Gen-Probe Incorporated | Compositions and methods for detecting bv-associated bacterial nucleic acid |
DE102011120550B4 (en) | 2011-12-05 | 2013-11-07 | Gen-Probe Prodesse, Inc. | Compositions, methods and kits for the detection of adenovirus nucleic acids |
CN104105711B (en) | 2012-02-10 | 2018-11-30 | 弗·哈夫曼-拉罗切有限公司 | Single-chain antibody and other heteromultimerics |
JP6237237B2 (en) * | 2012-02-17 | 2017-11-29 | 味の素株式会社 | Base protected oligonucleotide |
AU2013205010B2 (en) | 2012-02-24 | 2016-10-20 | Gen-Probe Incorporated | Detection of Shiga toxin genes in bacteria |
AU2013205110B2 (en) | 2012-04-24 | 2016-10-13 | Gen-Probe Incorporated | Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids |
AU2013205064B2 (en) | 2012-06-04 | 2015-07-30 | Gen-Probe Incorporated | Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid |
CA2871882A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
WO2014001324A1 (en) | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
AU2013205087B2 (en) | 2012-07-13 | 2016-03-03 | Gen-Probe Incorporated | Method for detecting a minority genotype |
CN104703620A (en) | 2012-07-20 | 2015-06-10 | 拉筹伯大学 | Method of diagnosis and treatment |
WO2014018885A2 (en) | 2012-07-27 | 2014-01-30 | Gen-Probe Incorporated | Dual reference calibration method and system for quantifying polynucleotides |
CA2883219C (en) | 2012-08-30 | 2020-12-29 | Gen-Probe Incorporated | Multiphase nucleic acid amplification |
US9783841B2 (en) | 2012-10-04 | 2017-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of target nucleic acids in a cellular sample |
AU2013205122B2 (en) | 2012-10-11 | 2016-11-10 | Gen-Probe Incorporated | Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid |
AU2013205090B2 (en) | 2012-12-07 | 2016-07-28 | Gen-Probe Incorporated | Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid |
CA2897474A1 (en) | 2013-01-24 | 2014-07-31 | California Institute Of Technology | Chromophore-based characterization and detection methods |
US10077475B2 (en) | 2013-01-24 | 2018-09-18 | California Institute Of Technology | FRET-based analytes detection and related methods and systems |
US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
US9976175B2 (en) | 2013-03-15 | 2018-05-22 | Gen-Probe Incorporated | Calibration method, apparatus and computer program product |
CN105392892A (en) | 2013-03-27 | 2016-03-09 | 六品科技公司 | Recombinant phage and bacterial detection methods |
JP2016521575A (en) * | 2013-06-14 | 2016-07-25 | ナノストリング テクノロジーズ,インコーポレイティド | Multiplexable tag-based reporter system |
JP2016521996A (en) | 2013-06-19 | 2016-07-28 | サンプルシックス テクノロジーズ,インコーポレイティド | Phage-based bacterial detection assay |
EP3033437B1 (en) | 2013-08-14 | 2023-11-08 | Gen-Probe Incorporated | Compositions and methods for detecting hev nucleic acid |
PL3227332T3 (en) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
AU2016205179B2 (en) | 2015-01-09 | 2021-06-17 | Gen-Probe Incorporated | Methods and compositions for diagnosing bacterial vaginosis |
CA2977821A1 (en) | 2015-03-16 | 2016-09-22 | Gen-Probe Incorporated | Methods and compositions for detecting bacterial nucleic acid and diagnosing bacterial vaginosis |
DK3362462T3 (en) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | IN SITUATION DETECTION OF NUCLEOTID VARIANTS IN HIGH NOISE SAMPLES, AND COMPOSITIONS AND PROCEDURES RELATED THEREOF |
AU2017205399C1 (en) | 2016-01-04 | 2023-06-15 | Gen-Probe Incorporated | Methods and compositions for detecting Candida species |
JP6803930B2 (en) | 2016-06-10 | 2021-01-06 | ジェン−プローブ・インコーポレーテッド | Compositions and Methods for Detecting ZIKA Viral Nucleic Acids |
US10450599B2 (en) | 2016-07-05 | 2019-10-22 | California Institute Of Technology | Fractional initiator hybridization chain reaction |
AU2017346854A1 (en) | 2016-10-19 | 2019-05-30 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying hepatitis C virus |
WO2018094171A1 (en) | 2016-11-21 | 2018-05-24 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying hepatitis b virus |
CA3055427C (en) | 2017-03-24 | 2022-12-13 | Gen-Probe Incorporated | Compositions and methods for detection of viral pathogens in samples |
EP4282985A3 (en) | 2017-03-24 | 2024-02-28 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying parainfluenza virus |
US11667978B2 (en) | 2017-06-07 | 2023-06-06 | Gen-Probe Incorporated | Detecting Babesia species nucleic acid in a sample |
CA3068994C (en) | 2017-07-10 | 2023-06-27 | Gen-Probe Incorporated | Analytical systems and methods for nucleic acid amplification using sample assigning parameters |
US11859257B2 (en) | 2017-08-11 | 2024-01-02 | Gen-Probe Incorporated | Compositions and methods for detecting Staphylococcus aureus |
CN111465707A (en) | 2017-11-17 | 2020-07-28 | 简·探针公司 | Compositions and methods for detecting C1orf43 nucleic acids |
US20200318171A1 (en) | 2017-12-15 | 2020-10-08 | Gen-Probe Incorporated | Compositions and Methods for Detecting Toxigenic Clostridium Difficile |
JP2021512303A (en) | 2018-01-29 | 2021-05-13 | ジェン−プローブ・インコーポレーテッド | Analytical systems and methods |
CN112654721A (en) | 2018-06-13 | 2021-04-13 | 简·探针公司 | Compositions and methods for detecting group B streptococcal nucleic acids |
US20210317515A1 (en) | 2018-07-10 | 2021-10-14 | Gen-Probe Incorporated | Methods and systems for detecting and quantifying nucleic acids |
WO2020028631A1 (en) | 2018-08-01 | 2020-02-06 | Gen-Probe Incorporated | Compositions and methods for detecting nucleic acids of epstein-barr virus |
US20210310059A1 (en) | 2018-08-08 | 2021-10-07 | Gen-Probe Incorporated | Compositions, methods and kits for detecting mycoplasma genitalium |
AU2019326462A1 (en) | 2018-08-21 | 2021-03-25 | Gen-Probe Incorporated | Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus |
EP3841222A1 (en) | 2018-08-24 | 2021-06-30 | Gen-Probe Incorporated | Compositions and methods for detecting bacterial nucleic acid and diagnosing bacterial vaginosis |
AU2019350777A1 (en) | 2018-09-27 | 2021-05-20 | Gen-Probe Incorporated | Compositions and methods for detecting Bordetella pertussis and Bordetellaparapertussis nucleic acid |
CN113195743A (en) | 2018-10-22 | 2021-07-30 | 简·探针公司 | Compositions and methods for amplifying, detecting or quantifying human polyoma virus BK virus |
TW202030333A (en) | 2018-12-20 | 2020-08-16 | 美商簡 探針公司 | Compositions and methods for detecting plasmodium species nucleic acid |
WO2020142347A2 (en) | 2018-12-31 | 2020-07-09 | Gen-Probe Incorporated | Systems and methods for filling multi-well cartridges with solid reagents |
US20220098647A1 (en) | 2019-03-22 | 2022-03-31 | Gen-Probe Incorporated | Compositions and Methods for Detecting Group A Streptococcus |
CA3176696A1 (en) | 2019-05-03 | 2020-11-12 | Gen-Probe Incorporated | Receptacle transport system for an analytical system |
US20220307093A1 (en) | 2019-07-03 | 2022-09-29 | Gen-Probe Incorporated | Oligonucleotides for use in determining the presence of trichomonas vaginalis in a sample |
EP4018004A1 (en) | 2019-08-23 | 2022-06-29 | Gen-Probe Incorporated | Compositions, methods and kits for detecting treponema pallidum |
CA3153514A1 (en) | 2019-09-05 | 2021-03-11 | Gen-Probe Incorporated | Detection of chlamydia trachomatis nucleic acid variants |
JP2023503946A (en) | 2019-12-09 | 2023-02-01 | ジェン-プローブ・インコーポレーテッド | Quantification of polynucleotide analytes from dried samples |
CA3167112A1 (en) | 2020-01-16 | 2021-07-22 | Dnae Diagnostics Limited | Compositions, kits and methods for isolating target polynucleotides |
CA3174532A1 (en) | 2020-03-04 | 2021-09-10 | Gen-Probe Incorporated | Compositions and methods for detecting sars-cov-2 nucleic acid |
US20230243001A1 (en) | 2020-07-17 | 2023-08-03 | Gen-Probe Incorporated | Detection of Macrolide-Resistant Mycoplasma Genitalium |
WO2022087257A2 (en) | 2020-10-21 | 2022-04-28 | Gen-Probe Incorporated | Fluid container management system |
US11873485B2 (en) | 2021-01-26 | 2024-01-16 | California Institute Of Technology | Allosteric conditional guide RNAs for cell-selective regulation of CRISPR/Cas |
WO2022241291A1 (en) | 2021-05-14 | 2022-11-17 | Gen-Probe Incorporated | Compositions and methods for detecting human adenovirus nucleic acid |
AU2022304654A1 (en) | 2021-07-01 | 2023-12-14 | Gen-Probe Incorporated | Enzyme formulations and reaction mixtures for nucleic acid amplification |
GB202110479D0 (en) | 2021-07-21 | 2021-09-01 | Dnae Diagnostics Ltd | Compositions, kits and methods for sequencing target polynucleotides |
GB202110485D0 (en) | 2021-07-21 | 2021-09-01 | Dnae Diagnostics Ltd | Compositions, kits and methods for sequencing target polynucleotides |
WO2023002203A1 (en) | 2021-07-21 | 2023-01-26 | Dnae Diagnostics Limited | Method and system comprising a cartridge for sequencing target polynucleotides |
WO2023010008A1 (en) | 2021-07-27 | 2023-02-02 | Gen-Probe Incorporated | Compositions and methods for detecting gastrointestinal pathogens |
EP4282980A1 (en) | 2022-05-23 | 2023-11-29 | Mobidiag Oy | Methods for amplifying a nucleic acid |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB215607A (en) * | 1923-06-11 | 1924-05-15 | Emory Winship | Improvements in or relating to steering mechanism for vehicles |
CA1219824A (en) * | 1981-04-17 | 1987-03-31 | David C. Ward | Modified nucleotides and methods of preparing and using same |
FI63596C (en) * | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER |
WO1984003285A1 (en) * | 1983-02-22 | 1984-08-30 | Molecular Biosystems Inc | Defined sequence single strand oligonucleotides incorporating reporter groups, process for the chemical synthesis thereof, and nucleosides useful in such synthesis |
GB8306426D0 (en) * | 1983-03-09 | 1983-04-13 | Malcolm A D B | Detecting polynucleotide sequence |
DK188184A (en) * | 1983-04-20 | 1984-10-21 | Enzo Biochem Inc | PROCEDURE FOR CREATING A COMPLEX OF BIOLOGICAL ACTIVE OR FUNCTIONAL COMPOUNDS AND USING THE COMPOUNDS |
CA1228811A (en) * | 1983-05-05 | 1987-11-03 | Robert G. Pergolizzi | Assay method utilizing polynucleotide sequences |
CA1256005A (en) * | 1983-09-26 | 1989-06-20 | W. Peter Hansen | Sandwich hybridization method for nucleic acid detection |
US4699876A (en) * | 1984-01-27 | 1987-10-13 | E. I. Du Pont De Nemours And Company | Nonradiometric polynucleotide probes |
FI71768C (en) * | 1984-02-17 | 1987-02-09 | Orion Yhtymae Oy | Enhanced nucleic acid reagents and process for their preparation. |
GB8405437D0 (en) * | 1984-03-01 | 1984-04-04 | Amersham Int Plc | Detecting polynucleotide sequences |
FR2567523B1 (en) * | 1984-07-12 | 1987-11-13 | Pasteur Institut | COVALENTLY BONDED POLYNUCLEOTIDES TO A SOLID SUPPORT, AND METHOD FOR THEIR PRODUCTION |
US4755458A (en) * | 1984-08-30 | 1988-07-05 | Enzo Biochem, Inc. | Composition and method for the detection of the presence of a polynucleotide sequence of interest |
US4563417A (en) * | 1984-08-31 | 1986-01-07 | Miles Laboratories, Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
US4828979A (en) * | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
FI72146C (en) * | 1985-01-02 | 1987-04-13 | Orion Yhtymae Oy | Procedure for Identifying Nucleic Acids. |
CA1272443A (en) * | 1985-02-22 | 1990-08-07 | Nanibhushan Dattagupta | Solution-phase dual hybridization assay for detecting polynucleotide sequences |
JP2609238B2 (en) * | 1985-05-02 | 1997-05-14 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | Methods and nucleic acid constructs for making reagent complexes useful for assaying a target nucleotide sequence |
JPH0723393B2 (en) * | 1985-05-15 | 1995-03-15 | アモコ・コーポレーション | Cytidine congener |
ES8707343A1 (en) * | 1985-06-13 | 1987-07-16 | Amgen | Method for performing nucleic acid hybridization assays. |
US4751177A (en) * | 1985-06-13 | 1988-06-14 | Amgen | Methods and kits for performing nucleic acid hybridization assays |
JPS622164A (en) * | 1985-06-25 | 1987-01-08 | シスカ・ダイアグノステイツクス・インコ−ポレ−テツド | Nucleic acid probe containing n4-(substituted amino) cytidine |
JP2509574B2 (en) * | 1985-08-15 | 1996-06-19 | アモコ・コーポレーション | Labeled nucleic acid |
-
1985
- 1985-12-11 US US06/807,624 patent/US4868105A/en not_active Expired - Lifetime
-
1986
- 1986-12-04 CA CA000524568A patent/CA1303033C/en not_active Expired - Lifetime
- 1986-12-10 ES ES90121584T patent/ES2160569T3/en not_active Expired - Lifetime
- 1986-12-10 AT AT86309622T patent/ATE113078T1/en not_active IP Right Cessation
- 1986-12-10 EP EP90121584A patent/EP0423839B1/en not_active Expired - Lifetime
- 1986-12-10 DE DE3650103T patent/DE3650103T2/en not_active Expired - Lifetime
- 1986-12-10 ES ES86309622T patent/ES2061441T3/en not_active Expired - Lifetime
- 1986-12-10 AT AT90121584T patent/ATE204288T1/en active
- 1986-12-10 DE DE3650760T patent/DE3650760T2/en not_active Expired - Lifetime
- 1986-12-10 EP EP86309622A patent/EP0225807B1/en not_active Expired - Lifetime
- 1986-12-11 JP JP61296524A patent/JP2655569B2/en not_active Expired - Fee Related
-
1991
- 1991-09-10 CA CA000616159A patent/CA1317207C/en not_active Expired - Fee Related
-
1993
- 1993-09-20 JP JP5233589A patent/JPH06339378A/en active Pending
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
US5876928A (en) * | 1978-04-13 | 1999-03-02 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
US5817786A (en) * | 1983-02-22 | 1998-10-06 | Molecular Biosystems, Inc. | Single-stranded labelled oligonucleotides of preselected sequences |
US5578717A (en) * | 1984-10-16 | 1996-11-26 | Chiron Corporation | Nucleotides for introducing selectably cleavable and/or abasic sites into oligonucleotides |
US5552538A (en) * | 1984-10-16 | 1996-09-03 | Chiron Corporation | Oligonucleotides with cleavable sites |
US5545730A (en) * | 1984-10-16 | 1996-08-13 | Chiron Corporation | Multifunctional nucleic acid monomer |
USRE37891E1 (en) * | 1986-10-23 | 2002-10-22 | Vysis, Inc. | Target and background capture methods with amplification for affinity assays |
US5656731A (en) * | 1987-10-15 | 1997-08-12 | Chiron Corporation | Nucleic acid-amplified immunoassay probes |
WO1989003891A1 (en) * | 1987-10-15 | 1989-05-05 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5624802A (en) * | 1987-10-15 | 1997-04-29 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5614362A (en) * | 1987-10-15 | 1997-03-25 | Chiron Corporation | Nucleic acid hybridization assay for hepatitis B virus DNA |
US5571670A (en) * | 1987-10-15 | 1996-11-05 | Chiron Corporation | Nucleic acid probes useful in detecting Chlamydia trachomatis and amplified nucleic acid hybridization assays using same |
EP0317077A1 (en) * | 1987-10-15 | 1989-05-14 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
EP0318255A3 (en) * | 1987-11-23 | 1990-07-18 | Eastman Kodak Company (A New Jersey Corporation) | Cuvette |
EP0318255A2 (en) * | 1987-11-23 | 1989-05-31 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Cuvette |
FR2642074A1 (en) * | 1989-01-20 | 1990-07-27 | Oris Ind | DERIVATIVES OF POLYHYDROXYL MOLECULES ALLOWING THE INTRODUCTION OF AT LEAST ONE BRANCHIFICATION IN AN OLIGONUCLEOTIDE |
WO1990008156A1 (en) * | 1989-01-20 | 1990-07-26 | Cis Bio International | Derivatives of polyhydroxylated molecules for introducing at least one ramification in an oligonucleotide |
WO1990013667A1 (en) * | 1989-04-18 | 1990-11-15 | Chiron Corporation | Improved amplified nucleic acid hybridization assays for hbv |
EP0421469A2 (en) * | 1989-10-06 | 1991-04-10 | Canon Kabushiki Kaisha | Method for separating nucleic acid |
EP0421469A3 (en) * | 1989-10-06 | 1993-02-24 | Canon Kabushiki Kaisha | Method for separating nucleic acid |
WO1991006674A1 (en) * | 1989-11-06 | 1991-05-16 | Scotgen Ltd. | Method and device for the detection of antibiotic resistance |
WO1991008307A1 (en) * | 1989-12-04 | 1991-06-13 | Microprobe Corporation | Enhanced capture of target nucleic acid by the use of oligonucleotides covalently attached to polymers |
WO1991017442A1 (en) * | 1990-05-04 | 1991-11-14 | Chiron Corporation | Protein-nucleic acid probes and immunoassays using same |
EP0541693A1 (en) * | 1990-07-27 | 1993-05-19 | Chiron Corporation | Large comb-type branched polynucleotides |
EP0523557A1 (en) * | 1991-07-16 | 1993-01-20 | Roche Diagnostics GmbH | Immobilisation of nucleic acids |
US6040193A (en) | 1991-11-22 | 2000-03-21 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US5681702A (en) * | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US7972579B2 (en) | 2003-07-04 | 2011-07-05 | F. Hoffmann-La Roche Ag | Device for the automatic opening and closing of reaction vessels |
US9738727B2 (en) | 2011-10-14 | 2017-08-22 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use |
US11512143B2 (en) | 2015-10-30 | 2022-11-29 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2061441T3 (en) | 1994-12-16 |
DE3650103D1 (en) | 1994-11-24 |
ATE113078T1 (en) | 1994-11-15 |
EP0225807A2 (en) | 1987-06-16 |
JP2655569B2 (en) | 1997-09-24 |
EP0423839B1 (en) | 2001-08-16 |
CA1317207C (en) | 1993-05-04 |
DE3650103T2 (en) | 1995-03-30 |
DE3650760T2 (en) | 2002-04-18 |
DE3650760D1 (en) | 2001-09-20 |
EP0225807A3 (en) | 1988-09-07 |
US4868105A (en) | 1989-09-19 |
ES2160569T3 (en) | 2001-11-16 |
EP0423839A2 (en) | 1991-04-24 |
ATE204288T1 (en) | 2001-09-15 |
JPS62188970A (en) | 1987-08-18 |
EP0423839A3 (en) | 1991-09-25 |
JPH06339378A (en) | 1994-12-13 |
CA1303033C (en) | 1992-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0225807B1 (en) | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein | |
EP0360940B1 (en) | Polynucleotide determination with selectable cleavage sites | |
US5093232A (en) | Nucleic acid probes | |
EP0469066B1 (en) | Improved nucleic acid hybridization assays for hbv employing amplification | |
US4910300A (en) | Method for making nucleic acid probes | |
US5849481A (en) | Nucleic acid hybridization assays employing large comb-type branched polynucleotides | |
EP0317077B1 (en) | Nucleic acid multimers and amplified nucleic acid hybridization assays using same | |
US4775619A (en) | Polynucleotide determination with selectable cleavage sites | |
EP0212951B1 (en) | Labelled nucleic acids | |
US5571670A (en) | Nucleic acid probes useful in detecting Chlamydia trachomatis and amplified nucleic acid hybridization assays using same | |
JP2801051B2 (en) | Methods and reagents for detecting nucleobase sequences | |
EP0292128A1 (en) | Improved DNA probes | |
JP2641322B2 (en) | Large comb-shaped branched polynucleotide | |
EP0703296B1 (en) | Polynucleotide determination by displacement of a strand on a capture probe | |
EP0610215A1 (en) | Polynucleotide determination with selectable cleavage sites | |
JP2749277B2 (en) | Nucleic acid multimer and amplified nucleic acid hybridization analysis method using the same | |
JP3140045B2 (en) | Improved amplified nucleic acid hybridization assay for HBV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19881003 |
|
17Q | First examination report despatched |
Effective date: 19900620 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 113078 Country of ref document: AT Date of ref document: 19941115 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3650103 Country of ref document: DE Date of ref document: 19941124 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2061441 Country of ref document: ES Kind code of ref document: T3 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO ROMA S.P.A. |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
26 | Opposition filed |
Opponent name: INSTITUT PASTEUR Effective date: 19950719 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: INSTITUT PASTEUR |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBO | Opposition rejected |
Free format text: ORIGINAL CODE: EPIDOS REJO |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: CHIRON CORPORATION TRANSFER- CHIRON DIAGNOSTICS CO |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
27O | Opposition rejected |
Effective date: 19990204 |
|
NLS | Nl: assignments of ep-patents |
Owner name: CHIRON DIAGNOSTICS CORPORATION |
|
NLR2 | Nl: decision of opposition | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20051121 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051207 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051216 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20051226 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051227 Year of fee payment: 20 Ref country code: CH Payment date: 20051227 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20051229 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20051230 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20060131 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20060202 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20060216 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20061209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20061210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20061211 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20061210 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20061211 |
|
BE20 | Be: patent expired |
Owner name: *CHIRON DIAGNOSTICS CORP. UNE SOCIETE DE L'ETAT DE Effective date: 20061210 |